Purple Biotech (PPBT) 20-F 23 Mar 20 2019 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2019shares
Document and Entity Information [Abstract]
Entity Registrant Name	Kitov Pharma Ltd.
Entity Central Index Key	0001614744
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	20-F
Document Period End Date	Dec. 31, 2019
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	L3
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-37643
Entity Common Stock, Shares Outstanding	19,564,449

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 4,385	$ 5,163
Short term deposits	10	1,521
Financial assets	2,000
Other current assets	1,907	1,830
Total current assets	8,302	8,514
Right to use assets	206
Fixed assets, net	38	37
Intangible assets	6,172	6,172
Total assets	14,718	14,723
Liabilities
Lease liability - short term	195
Accounts payable	1,245	705
Other payables	2,106	2,055
Derivative instruments		554
Total current liabilities	3,546	3,314
Non-current liabilities
Lease liability	28
Post-employment benefit liabilities	285	405
Total non - current liabilities	313	405
Equity
Share capital, no par value
Share premium	46,986	44,597
Receipts on account of warrants	9,874	7,982
Capital reserve for share-based payments	3,181	1,714
Capital reserve from transactions with related parties	761	761
Capital reserve from transactions with non- controlling interest	(859)	(859)
Accumulated loss	(49,522)	(43,672)
Equity attributable to owners of the Company	10,421	10,523
Non-controlling interests	438	481
Total equity	10,859	11,004
Total liabilities and equity	$ 14,718	$ 14,723

Consolidated Statements of Oper

Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Profit or loss [abstract]
Revenues	$ 1,000	$ 1,000	$ 100	[1]
Research and development expenses	2,674	5,268	4,640
Sales, general and administrative expenses	6,078	5,195	6,397
Reimbursement of legal fees	(596)	(743)
Other expenses (income)		(894)	1,029
Total operating expenses	8,156	8,826	12,066
Operating Loss	7,156	7,826	11,966	[1]
Net change in fair value of derivatives	(1,509)	(2,740)	1,049
Finance expense	181	576	26
Finance income	(151)	(93)	(128)
Finance expenses (income), net	(1,479)	(2,257)	947
Taxes expenses	216
Loss for the year	5,893	5,569	12,913
Other comprehensive loss
Re-measurement of defined benefit liability			95
Total comprehensive loss for the year	5,893	5,569	13,008
Loss attributable to:
Owners of the Company	5,850	5,200	12,177	[1]
Non-controlling interests	43	369	736
Total Loss attributable	5,893	5,569	12,913	[1]
Total comprehensive loss attributable to:
Owners of the Company	5,850	5,200	12,272	[1]
Non-controlling interests	43	369	736
Non-controlling interests	$ 5,893	$ 5,569	$ 13,008
Loss per share data
Basic and diluted loss per share - USD	$ 0.3	$ 0.39	$ 1.37	[2]
Number of shares used in calculating basic and diluted loss per share	19,367,484	14,205,301	9,456,952	[2]
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).
[2]	Restated to reflect a 20:1 reverse share split, that took place in January 2019, see Note 9A.

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Share Capital	Share premium	Receipts on account of warrants	Capital reserve for share-based payments	Capital reserve from transactions with related parties	Capital reserve from transactions with Non-controlling interest	Accumulated loss	Equity attributable to owners of parent [member]	Non-controlling interests	Total
Balance at Dec. 31, 2016		$ 30,826	$ 7,415	$ 583	$ 761		$ (26,200)	$ 13,385		$ 13,385
Transactions with owners of the company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs		2,174						2,174		2,174
Issuance of shares due to RSUs vesting		1,083		(1,083)
Share issuance due to an acquisition of a subsidiary (see Note 5)		1,800						1,800	2,016	3,816
Share-based payments		96		2,225				2,321		2,321
Total transactions with owners of the Company		5,153		1,142				6,295	2,016	8,311
Comprehensive loss for the year:
Loss for the year							(12,177)	(12,177)	(736)	(12,913)
Other comprehensive loss							(95)	(95)		95
Total comprehensive loss for the year							(12,272)	(12,272)	(736)	(13,008)
Balance at Dec. 31, 2017		35,979	7,415	1,725	761		(38,472)	7,408	1,280	8,688
Transactions with owners of the company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs		4,276						4,276		4,276
Issuance of shares due to RSUs vesting		299		(299)
Exercise of warrants		2,133						2,133		2,133
Share issuance due to an acquisition of a subsidiary (see Note 5)		1,856				(859)		997	(861)	136
Share-based payments		54		288				342	431	773
Transfer of derivative instrument from liability to equity			567					567		567
Total transactions with owners of the Company		8,618	567	(11)		(859)		8,315	(430)	7,885
Comprehensive loss for the year:
Loss for the year										(5,569)
Other comprehensive loss
Total comprehensive loss for the year							(5,200)	(5,200)	(369)	(5,569)
Balance at Dec. 31, 2018		44,597	7,982	1,714	761	(859)	(43,672)	10,523	481	11,004
Transactions with owners of the company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs		2,200		298				2,498		2,498
Issuance of shares due to RSUs vesting		104		(104)
Issuance of shares due to RSUs vesting, shares
Exercise of warrants		85	(42)					43		43
Share-based payments				1,273				1,273		1,273
Transfer of derivative instrument from liability to equity			1,934					1,934		1,934
Total transactions with owners of the Company		2,389	1,892	1,467				5,748		5,748
Comprehensive loss for the year:
Loss for the year							(5,850)	(5,850)	(43)	(5,893)
Total comprehensive loss for the year										(5,893)
Balance at Dec. 31, 2019		$ 46,986	$ 9,874	$ 3,181	$ 761	$ (859)	$ (49,522)	$ 10,421	$ 438	$ 10,859

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Loss for the year	$ (5,893)	$ (5,569)	$ (12,913)
Adjustments:
Depreciation	178	7	4
Finance expenses (income), net	(1,479)	(2,257)	947
Share-based payments	1,273	773	2,308
Expenses (income) in regards with settlement with a minority shareholder of a subsidiary (see Note 5)		(894)	1,000
Total adjustments	(5,921)	(7,940)	(8,654)
Changes in assets and liabilities:
Changes in other current assets	62	(1,111)	(273)
Changes in accounts payable	503	393	(491)
Changes in other payables	(77)	241	650	[1]
Changes in post-employment benefit liabilities	(148)	(63)	141
Changes in assets and liabilities, total	340	(540)	27
Net cash used in operating activities	(5,581)	(8,480)	(8,627)
Cash flows from investing activities:
Investment in financial assets and loan granted	(2,100)
Acquisition of a subsidiary (see Note 5)			(1,732)
Decrease in short term deposits	1,511	1,967	4,411
Interest received	151	93	106
Acquisition of fixed assets	(11)	(16)	(13)
Net cash provided by (used in) investing activities	(449)	2,044	2,772
Cash flows from financing activities:
Repayment of loans from related parties			(130)
Short-term credit from bank			(16)
Proceeds from issuance of ADSs	2,594	4,683	2,419
Share and ADS issuance expenses paid	(264)	(407)	(245)
Proceeds from issuance of warrants	3,406	3,467	1,107
Warrants issuance expenses paid	(347)	(301)	(114)
Receipts from warrant exercise	43	515
Repayment of lease liability	(171)
Interest paid	(28)	(169)	(26)
Net cash provided by financing activities	5,233	7,788	2,995
Net increase (decrease) in cash and cash equivalents	(797)	1,352	(2,860)
Cash and cash equivalents at the beginning of the year	5,163	3,947	6,758
Effect of translation adjustments on cash	19	(136)	49
Cash and cash equivalents at end of the year	4,385	5,163	3,947
Non- Cash activities:
Reclassification of warrants due to modification	$ 1,934	$ 567
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).

General

General	12 Months Ended
	Dec. 31, 2019
General [Abstract]
General	Note 1 - General Reporting entity A. Kitov Pharma Ltd. (hereinafter: "the Company The Company has two operating segments: (i) Oncology, which includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways involved in the development of cancer drug resistance mechanisms. (ii) Pain and Hypertension, which includes Consensi™, a combination drug approved by the FDA for marketing in the U.S and is partnered in the U.S, China and South Korea. The Company was incorporated in Israel as a private company in August 1968, and has been listed for trading on the Tel Aviv Stock Exchange since September 1978. In October 2012, the Company disposed of all of its previous operations, and in July 2013, the Company acquired shares of Kitov Pharmaceuticals Ltd. (hereinafter: " Kitov "the Acquisition" B. The Company's securities (American Depository Shares ("ADS") as well as Series A warrants) were listed for trading on the NASDAQ in November 2015. Each ADS represents 1 ordinary share with no par value following a reverse split in effect from January 4, 2019 (see Note 9A). Each warrant enables the purchase of 1 ADS. C. In December 2017, the Company completed its merger with Kitov, with the Company remaining as the surviving entity. The effective date of the merger was December 31, 2017. In January 2018, the Company changed its name from Kitov Pharmaceuticals Holdings Ltd to Kitov Pharma Ltd. The Company's address is One Azrieli Center, Round Tower, 132 Menachem Begin Road, Tel-Aviv 6701101 Israel. D. In January 2017, the Company acquired the majority of shares of TyrNovo Ltd. (hereinafter: " TyrNovo The Company together with TyrNovo are referred to, in these financial statements, as " the Group E. On March 14, 2019 the Company signed an agreement to acquire 100% of FameWave Ltd, a privately held biopharmaceutical Company with rights to develop CM-24, ("FameWave") from its shareholders in exchange for USD 10 million worth of its newly issued ADSs with a long term lock-up period, priced at USD 1.23 per ADS, plus 50% warrant coverage based on an exercise price of USD 1.98 per ADS with a 4 year term. The acquisition was subject to several conditions, which have been met as of January 7, 2020. In addition, the Company provided a loan to FameWave of USD 2 million that served mainly to pay cCAM BioTherapeutics Ltd., a wholly owned subsidiary of Merck Sharp and Dohme Corp., known as "MSD" in Israel, which discovered CM-24, and to finance budgeted expenses until the closing of the acquisition. See also Note 20B. F. Since incorporation through December 31, 2019, the Group has incurred losses and negative cash flows from operations mainly attributed to its development efforts and has an accumulated deficit of USD 49.5 million. The Group has financed its operations mainly through private and public financing rounds. Through December 31, 2019, the Company raised a total of USD 44.8 million net. Management anticipates that its existing capital resources will be adequate to satisfy liquidity requirements for the next 12 months. Subsequently, management's plans include pursuing alternative financing arrangements or reducing expenditures as necessary to meet the Company's future cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity.

Basis of Preparation of the Con

Basis of Preparation of the Consolidated Financial Statements	12 Months Ended
	Dec. 31, 2019
Basis of Preparation of the Financial Statements [Abstract]
Basis of Preparation of the Consolidated Financial Statements	Note 2 - Basis of Preparation of the Consolidated Financial Statements A. Statement of compliance with International Financial Reporting Standards The Group has prepared the consolidated financial statements in accordance with International Financial Reporting Standards (hereinafter: "IFRS"), as issued by the International Accounting Standard Board ("IASB"). These consolidated financial statements were approved by the board of directors on March 16, 2020. B. Functional and presentation currency These consolidated financial statements are presented in US dollars (USD), which is the Group's functional currency, rounded to the nearest one thousand, unless otherwise noted. The USD is the currency that represents the principal economic environment in which the Group operates. C. Use of estimates and judgment The preparation of consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Management prepares the estimates on the basis of past experience, various facts, external circumstances, and reasonable assumptions according to the pertinent circumstances of each estimate. The preparation of accounting estimates used in the preparation of the Group's consolidated financial statements requires management of the Group to make assumptions regarding circumstances and events that involve considerable uncertainty. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about assumptions made by the Group with respect to the future and other reasons for uncertainty with respect to estimates that have a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next financial year are included in the following notes: Estimate Principal assumptions Possible effects Reference Fair value measurement of non-trading derivatives Unobservable inputs used in the valuation model including standard deviation and discount rates Profit or loss from a change in the fair value of derivative financial instruments For information on a sensitivity analysis of level 3 financial instruments carried at fair value see Note 20B regarding financial instruments Identification of performance obligations in contracts with customers In order to identify distinct performance obligations in a contract with a customer, the Group uses judgment when it examines whether it is providing a significant service of integrating the goods or services in the contract into one integrated outcome. A change in the timing of recognizing revenue over the period of the contract. See Note 3I regarding revenue from contracts with customers. Assessment of probability of contingent liabilities Whether it is more likely than not that an outflow of economic resources will be required in respect of legal claims pending against the Company and its investees Reversal or creation of a provision for a claim For information on the Company's exposure to claims see Note 12B regarding contingent liabilities Recoverability of intangible assets The probability of regulatory considerations, commercial and legal considerations and financial and strategic considerations impermanent of the In-process research and development in profit or loss See Note 5 regarding intangible assets Note 2 - Basis of Preparation of the Consolidated Financial Statements (Cont'd) Fair value measurement The Group's management regularly reviews significant unobservable inputs and valuation adjustments, including obtaining valuations prepared by third parties and assessing the evidence to support the conclusion that these valuations meet the requirements of IFRS, including the level in the fair value hierarchy in which the valuations should be classified. Significant valuation issues are reported to the Group Audit Committee. When measuring the fair value of an asset or liability, the Group uses market observable data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: - Level 1: quoted prices in active markets for identical assets or liabilities. - Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. - Level 3: inputs for the asset or liability that are not based on observable market data. If the inputs used to measure the fair value of an asset or a liability might be categorized in different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. Further information about the assumptions made in measuring fair value of share based payments, financial asset and derivative instruments are included in Note 10 and Note 20B, respectively. D. Exchange rates and linkage bases Balances in foreign currency or linked thereto are included in the consolidated financial statements at the representative exchange rates, as published by the Bank of Israel, which were prevailing as of the statement of financial position date. Data on exchange rates are as follows: Representative exchange rate of USD (NIS/USD 1) Date of consolidated financial statements: December 31, 2019 3.456 December 31, 2018 3.748 December 31, 2017 3.467 Changes in exchange rates for the year ended: % December 31, 2019 (7.8 ) December 31, 2018 8.1 December 31, 2017 (9.8 ) E. Initial application of new standards, amendments to standards and interpretations As from January 1, 2019 the Group applies the new standards and amendments to standards described below. The Group has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective. IFRS 16, Leases As from January 1, 2019 (hereinafter: "the date of initial application") the Group applies International Financial Reporting Standard 16, Leases (hereinafter: "IFRS 16" or "the standard"), which replaced International Accounting Standard 17, Leases (hereinafter: "IAS 17" or "the previous standard"). The main effect of the standard's application is reflected in annulment of the existing requirement from lessees to classify leases as operating (off-balance sheet) or finance leases and the presentation of a unified model for lessees to account for all leases similarly to the accounting treatment of finance leases in the previous standard. Until the date of application, the Group classified all of the leases in which it is the lessee as operating leases, since it did not substantially bear all the risks and rewards from the assets. In accordance with IFRS 16, for agreements in which the Group is the lessee, the Group recognizes a right-of-use asset and a lease liability at the inception of the lease contract for all the leases in which the Group has a right to control identified assets for a specified period of time, other than exceptions specified in the standard. Accordingly, the Group recognizes depreciation and amortization expenses in respect of a right-of-use asset, tests a right-of-use asset for impairment in accordance with IAS 36 and recognizes financing expenses on a lease liability. Therefore, as from the date of initial application, lease payments relating to assets leased under an operating lease, which were presented as part of expenses in the statement of operations, are capitalized to assets and written down as depreciation and amortization expenses. The Group elected to apply the standard using the modified retrospective approach, with an adjustment to the balance of retained earnings as at January 1, 2019 and without a restatement of comparative data. In respect of all the leases, the Group elected to apply the transitional provisions such that on the date of initial application it recognized a liability at the present value of the balance of future lease payments discounted at its incremental borrowing rate at that date calculated according to the average duration of the remaining lease period as from the date of initial application, and concurrently recognized a right-of-use asset at the same amount of the liability, adjusted for any prepaid or accrued lease payments that were recognized as an asset or liability before the date of initial application. Therefore, application of the standard did not have an effect on the Group's equity at the date of initial application. Furthermore, as part of the initial application of the standard, the Group has chosen to apply the following expedients: (1) Not separating non-lease components from lease components and instead accounting for all the lease components and related non-lease components as a single lease component. (2) Not applying the requirement to recognize a right-of-use asset and a lease liability in respect of leases where the underlying asset has a low value. Impact of the application of IFRS 16 in the reporting period In measurement of the lease liabilities, the Group discounted lease payments using the nominal incremental borrowing rate at January 1, 2019. The discount rate used to measure the lease liability is 8%. As a result of applying IFRS 16, in relation to the leases that were classified as operating leases according to IAS 17, the Group recognized as at January 1, 2019 right-of-use assets and lease liabilities in the amount of approximately USD 400 thousand, respectively. As at December 31, 2019 the Group recognized right-of-use assets and lease liabilities in the amount of USD 206 thousand and USD 223 thousand, respectively. Furthermore, instead of recognizing lease expenses in relation to those leases, during the period ended December 31, 2019 the Group recognized additional depreciation expenses in the amount of USD 168 thousand, and additional financing expenses in the amount of USD 33 thousand. For further information on how the Group recognizes leases under IFRS 16, See Note 3N.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Significant Accounting Policies [Abstract]
Significant Accounting Policies	Note 3 - Significant Accounting Policies The accounting policies set out below have been consistently applied for all periods presented in these consolidated financial statements: A. Basis of consolidation 1. Business combination The Group accounts for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognized in profit or loss immediately. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities. The consideration transferred does not include amounts related to the settlement of pre-existing relationships. Such amounts are generally recognized in profit or loss. 2. Subsidiaries Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The consolidated financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. 3. Non-controlling interests Non-controlling interests are measured initially at their proportionate share of the acquiree's identifiable net assets at the date of acquisition. Changes in the Group's interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. 4. Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. B. Foreign currency transactions Transactions in foreign currency are translated to the functional currency of the Group at exchange rates as of the transaction dates. Monetary assets and liabilities denominated in foreign currency as of the reporting date are translated into the functional currency at the exchange rate as of the said date. Exchange rate differences with respect to monetary items are the differences between the amortized cost in the functional currency as of the start of the year, adjusted for the effective interest during the year, and the amortized cost in foreign currency, translated at the exchange rate as of the end of the year. Non-monetary items denominated in foreign currency and measured at historical cost, are translated using the exchange rate as of the transaction date. Exchange rate differences arising from translation into the functional currency are recognized on the statement of operations as financial expenses. C. Financial instruments 1. Non-Derivative financial instruments a. Non-derivative financial assets – policy applicable as from January 1, 2018 Initial recognition and measurement of financial assets The Group initially recognizes trade receivables and debt instruments issued on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition to one of the following measurement categories: assets at amortized cost; assets at fair value through other comprehensive income – investments in debt instruments; assets at fair value through other comprehensive income – investments in equity instruments; or assets at fair value through profit or loss. Financial assets are not reclassified in subsequent periods unless, and only if, the Group changes its business model for the management of financial debt assets, in which case the affected financial debt assets are reclassified at the beginning of the period following the change in the business model. b. Non-derivative financial assets – policy applicable before January 1, 2018 Initial recognition and measurement of financial assets The Group initially recognizes receivables and deposits on the date that they are created. All other financial assets acquired in a regular way purchase, are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument, meaning on the date the Group undertook to purchase or sell the asset. Non-derivative financial assets include: cash and cash equivalents, short term deposits and other receivables. Cash and cash equivalents include cash balances available for immediate use and call deposits. Cash equivalents include short-term highly liquid investments (with original maturities of three months or less) that are readily convertible into known amounts of cash and are exposed to insignificant risks of change in value. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. c. Non-derivative financial liabilities Non-derivative financial liabilities include: accounts payables and other payables. Initial recognition of financial liabilities The Group initially recognizes debt securities issued on the date that they originated. All other financial liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Subsequent measurement of financial liabilities Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Financial liabilities are designated at fair value through profit or loss if the Group manages such liabilities and their performance is assessed based on their fair value in accordance with the Group's documented risk management strategy, providing that the designation is intended to prevent an accounting mismatch, or the liability is a combined instrument including an embedded derivative. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled or transferred to equity. d. Derivative financial liabilities The Group holds derivative financial instruments that do not serve for hedging purposes. Measurement of derivative financial instruments Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are accounted for as described below. The changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these derivatives is based on an evaluation, and classified as level 3. D. Intangible assets 1. Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involve also plans or designs for the production of new or substantially improved products and processes. Development expenditure are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are recognized in profit and loss as expense. 2. Other intangible assets Other intangible assets, including in-process research and development in respect of the Company's acquisition of TyrNovo (see also Note 5), which have infinite useful lives, are measured at cost less accumulated impairment losses. 3. Amortization The Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether events and circumstances continue to support the decision that the intangible asset has an indefinite useful life. 4. Timing of impairment testing Once a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of each cash generating unit that contains goodwill, or intangible assets that have indefinite useful lives or are unavailable for use. E. Loss per share The Group presents loss per share data for its ordinary share capital. Loss per share is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding during the period. F. Employee benefits The Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance and pension companies, and they are classified as defined contribution plans and as defined benefit plans. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Other long-term employee benefits The Group's net obligation in respect of long-term employee benefits plans is calculated separately for each plan by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. G. Share-based payment transactions The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. H. Provisions A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. I. Revenue The Group recognizes revenue from upfront and milestone payments at the point in time the milestone criteria is met and collectability is probable. The revenue is measured according to the amount of the consideration to which the Group expects to be entitled. Identifying the contract The Group accounts for a contract with a customer only when the following conditions are met: (a) The parties to the contract have approved the contract (in writing, orally or according to other customary business practices) and they are committed to satisfying the obligations attributable to them; (b) The Group can identify the rights of each party in relation to the goods or services that will be transferred; (c) The Group can identify the payment terms for the goods or services that will be transferred; (d) The contract has a commercial substance (i.e. the risk, timing and amount of the entity's future cash flows are expected to change as a result of the contract); and (e) It is probable that the consideration, to which the Group is entitled to in exchange for the goods or services transferred to the customer, will be collected. For the purpose of section (e) the Group examines, inter alia, the percentage of the advance payments received and the spread of the contractual payments, past experience with the customer and the status and existence of sufficient collateral. If a contract with a customer does not meet all of the above criteria, consideration received from the customer is recognized as a liability until the criteria are met or when one of the following events occurs: the Group has no remaining obligations to transfer goods or services to the customer and any consideration promised by the customer has been received and cannot be returned; or the contract has been terminated and the consideration received from the customer cannot be refunded. Identifying performance obligations On the contract's inception date the Group assesses the goods or services promised in the contract with the customer and identifies as a performance obligation any promise to transfer to the customer one of the following: (a) Goods or services (or a bundle of goods or services) that are distinct; or (b) A series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. The Group identifies goods or services promised to the customer as being distinct when the customer can benefit from the goods or services on their own or in conjunction with other readily available resources and the Group's promise to transfer the goods or services to the customer is separately identifiable from other promises in the contract. In order to examine whether a promise to transfer goods or services is separately identifiable, the Group examines whether it is providing a significant service of integrating the goods or services with other goods or services promised in the contract into one integrated outcome that is the purpose of the contract. Determining the transaction price The transaction price is the amount of the consideration to which the Group expects to be entitled in exchange for the license and commercialization agreement. The Group takes into account the effects of all the following elements when determining the transaction price: variable consideration, the existence of a significant financing component, non-cash consideration, and consideration payable to the customer. Variable consideration The Group includes variable consideration, or part of it, in the transaction price only when it is highly probable that its inclusion will not result in a significant revenue reversal in the future when the uncertainty has been subsequently resolved. At the end of each reporting period and if necessary, the Group revises the amount of the variable consideration included in the transaction price. Right to use and right to access To determine whether the Group's promise to grant a license provides a customer with either a right to access the Group's IP or a right-to-use the Group's IP, the Group considers whether a customer can direct the use of, and obtain substantially all of the remaining benefits from, a license at the point in time at which the license is granted. A license is considered a "right-to-use" license when the customer maintains control of the IP upon its transfer. However, if the grantor of the license maintains involvement with the IP after its transfer, and the customer cannot direct the use of, and obtain substantially all of the remaining benefits from the license, then the license is considered a right-to-access license. The license granted by the Company, which relates to its product is granted to a third party which can obtain direct use of, and substantially all of the remaining benefits from the license at the point in time at which the license is granted. The Group will not continue to be involved in any activities that significantly affect the IP at the specific territory. Therefore recognized the license granted as right-to-use license. Principal or agent When another party is involved in providing goods or services to the customer, the Group examines whether the nature of its promise is a performance obligation to provide the defined goods or services itself, which means the Group is a principal and therefore recognizes revenue in the gross amount of the consideration, or to arrange that another party provide the goods or services which means the Group is an agent and therefore recognizes revenue in the amount of the net commission. The Group engaged with a third party to manufacture its products for the Group's customer ("the Manufacturing Agreement"). The Group is a principal when it controls the promised goods or services before their transfer to the customer. Indicators that the Group controls the goods or services before their transfer to the customer include, inter alia, as follows: the Group is the primary obligor for fulfilling the promises in the contract; the Group has inventory risk before the goods or services are transferred to the customer; and the Group has discretion in setting the prices of the goods or services. The above indicates that in the Manufacturing Agreement the Group is an agent and therefore it recognizes such revenues on a net basis. Contract modifications A contract modification is a change in the scope or price (or both) of a contract that was approved by the parties to the contract. A contract modification can be approved in writing, orally or be implied by customary business practices. A contract modification can take place also when the parties to the contract have a disagreement regarding the scope or price (or both) of the modification or when the parties have approved the modification in scope of the contract but have not yet agreed on the corresponding price modification. The Group accounts for a contract modification as an adjustment of the existing contract since the remaining goods or services after the contract modification are not distinct and therefore constitute a part of one performance obligation that is partially satisfied on the date of the contract modification. The effect of the modification on the transaction price and on the rate of progress towards full satisfaction of the performance obligation is recognized as an adjustment to revenues (increase or decrease) on the date of the contract modification, meaning on a catch-up basis. Royalties The Company recognizes revenue for sales-based royalties promised in exchange for a license of intellectual property when the later of the following events occurs: (a) the subsequent sale occurs; or (b) the performance obligation to which some or all of the sales-based royalties has been satisfied. The Company has yet to recognize revenues from royalties. J. Financing income and expense Finance income comprises changes in the fair value of the financial liability through profit and loss, and income from short term deposits. Finance expenses include loss from exchange rate differences. Interest expense is recognized, using the effective interest method. In the statements of cash flows, interest received is presented as part of cash flows from investing activities and interest paid is presented as part of cash flows from financing activities. K. Equity Incremental costs directly attributable to an expected issuance of an instrument that will be classified as equity are recognized as an asset in deferred expenses in the statement of financial position. The costs are deducted from the equity upon the initial recognition of the equity instruments, or are expensed as financing expenses in the statement of operations when the issuance is no longer expected to take place. L. Issuance of units of securities The consideration received from the issuance of units of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is allocated to equity. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described above. M. Income tax expense Income tax comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that they relate to a business combination, or are recognized directly in equity or in other comprehensive income to the extent they relate to items recognized directly in equity or in other comprehensive income. Current taxes Current tax is the expected tax payable (or receivable) on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date. Current taxes also include taxes in respect of prior years and any tax arising from dividends. Deferred taxes A deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets that were not recognized are reevaluated at each reporting date and recognized if it has become probable that future taxable profits will be available against which they can be utilized. N. Leases Policy applicable as from January 1, 2019 Determining whether an arrangement contains a lease On the inception date of the lease, the Group determines whether the arrangement is a lease or contains a lease, while examining if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. In its assessment of whether an arrangement conveys the right to control the use of an identified asset, the Group assesses whether it has the following two rights throughout the lease term: (a) The right to obtain substantially all the economic benefits from use of the identified asset; and (b) The right to direct the identified asset's use. For lease contracts that contain non-lease components, such as services or maintenance, that are related to a lease component, the Group elected not to separate non-lease components from lease components and instead accounting for all the lease components and related non-lease components as a single lease component. Leased assets and lease liabilities Contracts that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these payments do not include certain variable lease payments), and concurrently recognizes a right-of-use asset at the same amount of the lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease. Since the interest rate implicit in the Group's leases is not readily determinable, the incremental borrowing rate of the lessee is used. Subsequent to initial recognition, the right-of-use asset is accounted for using the cost model, and depreciated over the shorter of the lease term or useful life of the asset. The Group has elected to apply the practical expedient by which short-term leases of up to one year and/or leases in which the underlying asset has a low value, are accounted for such that lease payments are recognized in profit or loss on a straight-line basis, over the lease term, without recognizing an asset and/or liability in the statement of financial position. The lease term The lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably certain that the lessee will or will not exercise the option, respectively. Variable lease payments Variable lease payments that depend on an index or a rate, are initially measured using the index or rate existing at the commencement of the lease and are included in the measurement of the lease liability. When the cash flows of future lease payments change as the result of a change in an index or a rate, the balance of the liability is adjusted against the right-of-use asset. Other variable lease payments that are not included in the measurement of the lease liability are recognized in profit or loss in the period in which the event or condition that triggers payment occurs. Depreciation of right-of-use asset After lease commencement, a right-of-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over the useful life or contractual lease period, whichever earlier, as follows: ● Buildings 2 years ● Motor Vehicles 2-3 years Policy applicable before January 1, 2019 Determining whether an arrangement contains a lease At inception or upon reassessment of an arrangement, the Group determines whether such an arrangement is or contains a lease. An arrangement is a lease or contains a lease if the following two criteria are met: ● The fulfillment of the arrangement is dependent on the use of a specific asset or assets; and ● The arrangement contains rights to use the asset. At inception or upon reassessment of the arrangement, the Group separates payments and other consideration required by such an arrangement into those for the lease and those for other elements on the basis of their relative fair values. If the Group concludes for a finance lease that it is impracticable to separate the payments reliably, an asset and a liability are recognized at an amount equal to the fair value of the underlying asset. Subsequently the liability is reduced as payments are made and an imputed finance charge on the liability is recognized using the buyer's incremental borrowing rate. Other leases are classified as operating leases, and the leased assets are not recognized on the Group's statement of financial position. Lease payments Payments made under operating leases, other than conditional lease payments, are recognized in profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease expense on a straight-line basis, over the term of the lease. Minimum lease payments made under operating leases are recognized in profit or loss as incurred. O. New standards and interpretations not yet adopted (1) IAS 1 Presentation of Financial Statements Amendment to IAS 1, Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current The Amendment replaces certain classification requirements for current or non-current liabilities. Thus, for example, according to the Amendment, a liability will be classified as non-current when the entity has the right to defer settlement for at least 12 months after the reporting period, and it "has substance" and is in existence at the end of the reporting period. A right is in existence at the end of the reporting period only if the entity complies with conditions for deferring settlement at that date. Furthermore, the Amendment clarifies that the conversion option of a liability will affect its classification as current or non-current, other than when the conversion option is recognized as equity. The Amendment is effective for reporting periods beginning on or after January 1, 2022 and is applicable retrospectively, including an amendment to comparative data. The Group is examining the effects of the Amendment on the consolidated financial statements with no plans for early adoption. (2) Amendment to IFRS 3, Business Combinations The Amendment clarifies whether a transaction to acquire an operation is the acquisition of a "business" or an asset. For the purpose of this examination, the Amendment added an optional concentration test so that if substantially all of the fair value of the acquired assets is concentrated in a single identifiable asset or a group of similar identifiable assets, the acquisition will be of an asset. In addition, the minimum requirements for definition as a business have been clarified, such as for example the requirement that the acquired processes be substantive so that in order for it to be a business, the operation shall include at least one input element and one substantive process, which together significantly contribute to the ability to create outputs. Furthermore, the Amendment narrows the reference to the outputs element required in order to meet the definition of a business and added examples illustrating the aforesaid examination The Amendment is effective for transactions to acquire an asset or business for which the acquisition date is in annual periods beginning on or after January 1, 2020, with earlier application being permitted. In the opinion of the Group, application of the Amendment will may have a material effect on the accounting treatment of future acquisitions of operations.

Operating Segments

Operating Segments	12 Months Ended
	Dec. 31, 2019
Disclosure of operating segments [abstract]
Operating Segments	Note 4 - Operating Segments Since 2018 the chief operating decision marker (CODM) has started to review the results of two reportable segments, as described below, which form the Group’s strategic business units. The strategic business units offer different products and services and the allocation of resources and evaluation of performance are managed separately because they require different technology and marketing strategies. For each of the strategic business units, the Group’s CODM reviews internal management reports on at least a quarterly basis. The following summary describes the operations in each of the Group’s operating segments: ● Pain and Hypertension – Includes development and marketing of Consensi TM ● Oncology – Includes development of a small molecule that has demonstrated in pre-clinical studies the potential to overcome resistance to multiple anti-cancer drugs. The accounting policies of the operating segments are the same as described in Note 3 regarding significant accounting policies. Performance is measured based on segment operating results as included in reports that are regularly reviewed by the chief operating decision maker. Segment results are used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within these industries. Segment results reported to the chief operating decision maker includes revenue and research and development expenses which are directly attributable to a segment on a reasonable basis. Information about reportable segments Information regarding the results of each reportable segment is included below. For the year ended December 31, 2019 Pain and Hypertension Oncology Total reportable segments Reconciliations (*) Total consolidated USD in thousands Revenues 1,000 - 1,000 - 1,000 Research and development expenses 395 2,041 2,436 238 2,674 Operating loss 3,068 2,815 5,883 1,273 7,156 Finance income, net (1,479 ) Tax Expenses 216 Loss for the year 5,893 For the year ended December 31, 2018 Pain and Hypertension Oncology Total reportable segments Reconciliations (*) Total consolidated USD in thousands Revenues 1,000 - 1,000 - 1,000 Research and development expenses 2,185 2,537 4,722 546 5,268 Operating loss 4,730 3,217 7,947 (121 ) 7,826 Finance income, net (2,257 ) Loss for the year 5,569 For the year ended December 31, 2017 Pain and Hypertension Oncology Total reportable segments Reconciliations (*) Total consolidated USD in thousands Revenues 100 - 100 - 100 Research and development expenses 2,603 1,328 3,931 709 4,640 Operating loss 6,674 1,951 8,625 3,341 11,966 Finance income, net 947 Loss for the year 12,913 (*) Includes employees share based expenses and other expenses/income related to rights granted to Taoz. Information on geographical segments In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of customers. Revenues in 2019 are from the U.S and in each of 2018 and 2017 from the far-east. For further information see Note 13. All of the Group’s non-current assets are located in Israel.

Subsidiary

Subsidiary	12 Months Ended
	Dec. 31, 2019
Subsidiary [Abstract]
Subsidiary	Note 5 - Subsidiary A. On January 13, 2017, the Company completed its acquisition from Goldman Hirsh Partners Ltd ("GHP") of a controlling interest in TyrNovo, a privately-owned Israeli company, which is developing NT-219, a small molecule that has demonstrated in pre-clinical studies, the potential to overcome resistance to multiple anti-cancer drugs. Pursuant to the terms of the transaction, the Company issued to GHP 564,625 of its Ordinary Shares (the "Consideration Shares") and paid GHP aggregate cash proceeds of approximately USD 2 million (the "Cash Consideration") in exchange for 9,570 Ordinary Shares in TyrNovo, that represented approximately 65% of TyrNovo's shares. In addition, the Company was assigned a loan in the amount of USD 101 thousand which had been made by GHP to TyrNovo, (the "TyrNovo Acquisition"). USD 167 thousand of the Cash Consideration was held back by the Company pending the fulfillment of certain conditions as agreed to between the Company and GHP. During 2019 the Company and GHP signed an agreement, according to which the Company paid GHP USD 91 thousand and the remaining amount of USD 76 thousand was retained by the Company to cover any future claims it might have with regards of any matter the above amount was withheld for and is waived by GHP. The Company has written off this remaining liability. All of the Consideration Shares were held in escrow in order to ensure the fulfillment of certain post-closing undertakings and to satisfy indemnification claims and other liabilities the Company may become subject to as a result of the TyrNovo Acquisition. In February 2019, the Consideration Shares were released from the escrow. The acquisition was accounted for as an asset purchase as it does not meet the definition of a business combination in accordance with IFRS 3. (1) Consideration The following summarizes the acquisition date fair value of each major class of consideration: USD thousands Cash 2,000 Equity instruments issued (564,625 Ordinary Shares) (1) 1,800 Assignment of loan to the Company (101 ) Total consideration transferred 3,699 (1) The fair value of the Ordinary Shares issued was based on the listed share price of the Group on January 11, 2017 of approximately USD 3.19 per share. (2) Identifiable assets acquired and liabilities assumed The following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition: USD thousands Current assets 21 Fixed assets, net 3 Intangible assets (2) 6,172 Short-term credit from bank (16 ) Trade payables (123 ) Other payables (212 ) Long-term related parties (130 ) Total net identifiable assets 5,715 (2) In-process research and development Purchased in-process research and development expense represents the value assigned to research and development projects, which were commenced but not yet completed at the date of acquisition. Technological feasibility for these projects has not been established and they have no alternative future use in research and development activities or otherwise. B. Settlement with a minority shareholder On February 9, 2017, subsequent to the acquisition of TyrNovo, the Company, TyrNovo and Taoz - Company for Management and Holdings of Companies Ltd. ("Taoz"), a shareholder owning at that time approximately 4% of TyrNovo, entered into a settlement arrangement in response to a motion filed by Taoz on January 19, 2017. Pursuant to the settlement arrangement, the parties agreed, among other matters, as follows: Taoz was entitled to be issued an additional 77 ordinary shares of TyrNovo, representing 0.5% of the issued and outstanding share capital of TyrNovo immediately following this issuance. The shares were issued in February 2017 and were measured at a fair value of USD 29 thousand. Taoz had the right during a defined period to invest an additional USD 1,750,000 (the "Deferred Investment") by way of convertible loans, with conversion terms defined under various circumstances, including the possibility of conversion at a price per share reflecting a 30% discount off the price per share paid in a subsequent financing round, and the possibility of conversion at a price per TyrNovo share reflecting a TyrNovo company valuation of USD 13,500,000. In the event that a defined milestone is achieved, and Taoz did not invest the Deferred Investment, then the Company has the right to acquire all of Taoz's holdings in TyrNovo at a price per share of USD 476.48. The Company provided to Taoz a put option to sell to the Company up to 50% of the TyrNovo shares issued to Taoz, exercisable during a period of 90 days from the publication by TyrNovo of the results of Phase I clinical trials, for a price per TyrNovo share equal to USD 1,600, either in ordinary shares of the Company or, at the Company' sole discretion, in cash; upon the expiration of the 90 day exercise period, the put option, if not exercised by Taoz, shall expire and no longer be valid. The rights granted to Taoz by the Company were valued at the date of agreement at USD 1,000 thousand and were charged to Other Expenses. The value of these rights as of December 31, 2017 was estimated at USD 1,030 thousand. The net change in value of this liability in the amount of USD 30 thousand was charged to Finance Expenses, as well as other expenses in the amount of USD 29 thousand value of shares issued to Taoz in the consolidated financial statements for the year ended December 31, 2017. Regarding valuation techniques and significant unobservable inputs, see Note 20B. In regards with the acquisition of Taoz's shares in TyrNovo, see Note 5C below. In October 2017, the Company signed an agreement for the acquisition of an additional 27% stake in TyrNovo (the "Newly Acquired TyrNovo Shares"), from a group of unaffiliated minority shareholders of TyrNovo, who collectively held 4,024 ordinary shares, or approximately 27%, of TyrNovo. In exchange for these Newly Acquired TyrNovo Shares, the Company issued to these unaffiliated minority shareholders of TyrNovo, in aggregate, 658,484 newly issued ordinary shares of the Company, which, at that time, represented approximately 6% of the Company's issued and outstanding share capital . The closing of this transaction took place on March 15, 2018, following which the Company held approximately 91.9% of TyrNovo's issued and outstanding ordinary shares. The carrying amount of TyrNovo's net assets in the consolidated financial statements on the date of the acquisition was USD 2,821 thousand. The Group recognized a decrease in non-controlling interests of USD 768 thousand, an increase in share premium of USD 1,483 thousand and a decrease in a capital reserve for transactions with non-controlling interest of USD 715 thousand. C. In June 2018, the Company signed an agreement with a minority shareholder in TyrNovo, Taoz, for the acquisition of its holding in TyrNovo, which was approximately 4.1% of TyrNovo's share capital. In exchange for these shares and for the waiving of investment rights and put options it was previously granted, which are described in Note 5B, the Company issued to Taoz 140,845 newly issued ordinary shares of the Company. The fair value of the shares issued as consideration for the acquisition of TyrNovo Shares amounted to USD 237 thousand. The fair value of the shares issued in consideration for waving the rights amounted to USD 136 thousand. As part of the agreement, the Company committed to register the newly issued shares for trading. The registration statement, registering the Company's ADSs representing the newly issued shares for trading, was declared effective by the SEC as of August 8, 2018. In accordance with the agreement, the Company paid to Taoz in cash the difference between the share price of Kitov's shares on the closing date to that on the registration date, which amounted to USD 160 thousand. The cash payment was recorded to finance expenses. The carrying amount of TyrNovo's net assets in the consolidated financial statements on the date of the acquisition was USD 1,977 thousand. The Group recognized a decrease in non-controlling interests of USD 93 thousand, an increase in share premium of USD 237 thousand and a decrease in a capital reserve for transactions with non-controlling interest of USD 144 thousand. In addition, the Company derecognized the derivative liability of USD 1,030 thousand, recognized an amount of USD 894 thousand as other income and an increase in share premium of USD 136 thousand deriving from the waiving of the rights, as described above. The closing of this transaction took place on June 15, 2018, following which the Company held approximately 97.4% of TyrNovo's issued and outstanding ordinary shares. D. Non-controlling interests Non-controlling interests are presented based on their proportionate interest in the recognized amount of the assets and liabilities of TyrNovo. E. The following is condensed information regarding TyrNovo: Incorporated and Group's ownership equity TyrNovo Ltd. Israel 98.47 % During 2019 TyrNovo issued 13,750 shares to Kitov which increase the Company's direct ownership of equity from 97.6% to 98.47%.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2019
Cash and cash equivalents [abstract]
Cash and Cash Equivalents	Note 6 - Cash and Cash Equivalents As of December 31 2019 2018 USD thousands Balance in USD 4,279 4,410 Balance in other currencies 106 753 Total cash and cash equivalents 4,385 5,163

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2019
Other Current Assets [Abstract]
Other Current Assets	Note 7 - Other Current Assets As of December 31 2019 2018 USD thousands Receivables, see Note 14 1,493 - Government authorities 182 81 Reimbursement of legal fees receivable - 743 Prepaid fee to the Food and Drug Administration - 930 Prepaid expenses and other receivables 232 76 Total other current assets 1,907 1,830

Other Payables

Other Payables	12 Months Ended
	Dec. 31, 2019
Trade and other payables [abstract]
Other Payables	Note 8 - Other Payables As of December 31 2019 2018 USD thousands Contract liabilities, see Note 14 961 - Due to related parties - payroll related 587 910 Due to GHP (Note 5A) - 167 Accrued expenses 255 852 Government authorities 36 65 Payroll related payables 267 61 2,106 2,055

Equity

Equity	12 Months Ended
	Dec. 31, 2019
Changes in equity [abstract]
Equity	Note 9 - Equity A. On December 19, 2018 in a shareholders' general meeting, it was resolved to consolidate the Company's authorized and paid-in share capital in a 20:1 ratio, in a way that every 20 shares with no par value were consolidated into one share with no par value. The said reverse share split took place on January 4, 2019. Following the reverse share split, the Company's authorized share capital is 250,000,000 ordinary shares, with no par value, and 50,000,000 non-voting senior preferred shares, with no par value, divided into 5 classes of 10,000,000 preferred shares in each class. In these consolidated financial statements, all numbers of shares reflect the reverse share split retrospectively. B. The Company's share capital As of December 31 As of December 31 Number of shares in thousands Authorized Issued Authorized Issued Ordinary shares, no par value 250,000 19,564 250,000 16,099 Class A preferred shares, no par value 10,000 - 10,000 - Class B preferred shares, no par value 10,000 - 10,000 - Class C preferred shares, no par value 10,000 - 10,000 - Class D preferred shares, no par value 10,000 - 10,000 - Class E preferred shares, no par value 10,000 - 10,000 - C. Changes in share capital during the year For the year ended December 31 2019 2018 2017 Number of shares in thousands Issued as at January 1 16,009 11,222 7,662 Issuance of ADSs (See D below) 3,429 3,260 2,432 Issuance of shares (See Note 5) - 799 565 Vesting of RSUs 97 121 563 Exercise of warrants 29 607 - Issued as at December 31 19,564 16,009 11,222 D. Financing rounds 1. In January 2019, in a registered direct offering on the NASDAQ, the Company raised USD 6 million gross (approximately USD 5.1 million net of placement agent fees and other offering related expenses). Part of the issuance expenses were warrants issued to the placement agent in the amount of USD 298 thousand were recorded in equity. USD 129 thousand were recorded net of share premium and USD 169 thousand were recorded to finance expense. In this registered direct offering, the Company issued 3,428,572 ADSs and, in a concurrent private placement, 2,571,430 non-listed warrants to purchase 2,571,430 ADSs. Each non-listed warrant is exercisable until July 15, 2024 at an exercise price of USD 2.00 per ADS. The ADSs issued were recorded in equity in an amount of USD 2,200 thousand, net of issuance expenses. The warrants were considered a derivative instrument (due to a cashless exercise feature), and were recorded as a liability in the amount of USD 3,406 thousand. Issuance expenses related to the warrants, in the amount of USD 515 thousand were recorded to finance expense. During September 2019, the warrants were listed for trading, as a result the cashless feature expired. Therefore the Company reclassified the warrants to equity according to the warrants fair value on the listing date. The changes in the warrants fair value was recorded as financial income. The warrants fair value on the listing date was USD 1,273 thousand. See also Note 20B. 2. In June 2018, in a registered direct offering on the NASDAQ, the Company raised a gross amount of USD 8.1 million (approximately USD 7.4 million net of placement agent fees and other offering related expenses). In this registered direct offering, the Company issued 3,260,000 ADSs and, in a concurrent private placement, 1,630,000 non-listed warrants to purchase 1,630,000 ADSs. Each non-listed warrant is exercisable until December 5, 2023 at an exercise price of USD 2.80 per ADS. The ADS's issued were recorded in equity in an amount of USD 4,276 thousand, net of issuance expenses. The warrants were considered a derivative instrument (due to a cashless exercise feature) and were recorded as a liability in the amount of USD 3,467 thousand. Issuance expenses related to the warrants, in the amount of USD 301 thousand were recorded to finance expenses. During September 2019, the warrants were listed for trading, as a result the cashless feature expired. Therefore the Company reclassified the warrants to equity according to the warrants fair value on the listing date. The changes in the warrants fair value was recorded as financial income. The warrants fair value on the listing date was USD 661 thousand. See also Note 20B. 3. In July 2017, in a registered direct offering on the NASDAQ, the Company raised a gross amount of USD 3.5 million (approximately USD 3.1 million net of placement agent fees and other In this registered direct offering, the Company issued 2,431,746 ADSs in a concurrent private placement and 1,215,873 non-listed warrants to purchase 1,215,873 ADSs. Each non-listed warrant is exercisable until January 14, 2023 at an exercise price of USD 1.50 per ADS. The ADS's issued were recorded in equity and in an amount of USD 2,174 thousand. The warrants were considered a derivative instrument (due to a cashless exercise feature) and were recorded as a liability. During August 2018, the warrants were listed for trading, as a result the cashless feature expired. Therefore the Company reclassified the warrants to equity according to the warrants fair value on the listing date. The changes in the warrants fair value was recorded as financial income. The warrants fair value on the listing date was USD 567 thousand. See also Note 20B. E. Other equity transactions 1 During the reporting period, the Company issued 97 thousand ordinary shares on account of vested RSUs granted in 2017 and 2018. See also Note 10A. 2. During the reporting period, 29 thousand warrants, issued in July 2017, were exercised into 29 thousand shares for a consideration of USD 43 thousand. Subsequently, an amount of USD 42 thousand was recorded to share premium against receipts on accounts of warrants. 3. During 2018 343 thousand warrants, issued in July 2017, were exercised into 343 thousand shares for a consideration of USD 515 thousand. In addition, 484 thousand warrants, issued in July 2017, were exercised into 264 thousand shares on a cashless exercise, and an amount of USD 1,618 thousand was recorded to share premium against derivative liabilities. 4. During 2018 the Company issued 121 thousand ordinary shares on account of vested RSUs granted in 2017. See also Note 10A. 5. On October 30, 2017, the Company issued to a vendor of the Company, in consideration for services provided by the vendor to the Company, 67,367 ADSs. The fair value of the services provided was measured at USD 150 thousand, out of which, USD 96 were recorded as share premium against general and administrative expenses in 2017 and USD 54 thousand were recorded as share premium against general and administrative expenses in 2018. 6. During October and December 2017, the Company issued 496,533 ordinary shares on account of vested RSUs. See also Note 10. F. Non-controlling interests The following table summarizes the information relating to a subsidiary that has non-controlling interests, before any intra-group eliminations: December 31 December 31 TyrNovo Ltd. in USD thousand Non-controlling interests percentage 1.53 % 2.4 % Non-current assets 24 9 Current assets 192 415 Current liabilities (646 ) (4,120 ) Net assets (430 ) (3,696 ) Net assets attributable to non-controlling interests (7 ) (89 ) Loss for the year 2,847 3,688 Loss allocated to non-controlling interests 43 369

Share-based Payment Arrangement

Share-based Payment Arrangements	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangements [Abstract]
Share-based Payment Arrangements	Note 10 - Share-based Payment Arrangements A. On December 23, 2019, the Company granted 400 thousand options to the Chairman of the Board. The options have an exercise price of USD 0.814 per one ordinary share, and will vest during 3 years from the grant date. The options are exercisable for 7 years from grant date. The fair value of these options as of the grant date was measured at USD 207 thousand. During March and April 2019, the board of directors of the Company approved the grant of 3,162 thousand options to directors, employees and consultants. The options have an exercise price of USD 1.28 – 1.64 per one ordinary share, and will vest during 3 years from the date of grant. The options are exercisable for 5-7 years from grant date. The fair value of these options as of the grant date was measured at USD 2,677 thousand. Those options that were granted to directors were approved by the shareholders of the Company in April 2019. In addition, the Company granted 61 thousand options to Tmura, an Israeli charity organization, the options have an exercise price equals USD 6 per ordinary share, and were immediately vested at the date of grant. The fair value of these options as of the grant date was measured at USD 56 thousand. On November 20, 2018, the Company granted 159,759 options and 59,720 RSUs to two executives. The RSUs and options have a vesting period of 3 years from the commencement of the offeree's engagement with the Group, with a one-year cliff for the first one-third of the vested amount, and over 8 quarters thereafter. The exercise period is 5 years from the date of the grant. The options shall have an exercise price equals to USD 1.59 per one ordinary share. 34,825 thousand RSUs were fully vested at the time of the grant. The fair value of these RSUs and options at the date of the grant was measured at USD 71 thousand and USD 127 thousand, respectively. On August 15, 2017, the Company's Board of Directors approved grants of 17 thousand RSUs and 29 thousand options to two consultants. The RSUs and/or options have a vesting period of 3 years from the commencement of the service provider's engagement, with a one-year cliff for the first one-third of the vested amount, and over 8 quarters thereafter. The exercise period is 7 years from the date of the grant. The options shall have an exercise price equals to USD 1.84 per one ordinary share. 29 thousand options and 9 thousand RSUs were fully vested at the time of the grant. The fair value of these RSUs and options at the date of the grant was measured at USD 32 thousand and USD 31 thousand, respectively. In addition, on August 15, 2017, the Company's Board of Directors granted of 42 thousand RSUs and 16 thousand options to one consultant . In June 2017, the Company's board of directors decided to amend the Company's 2016 Equity-Based Incentive Plan (the "Plan") to increase the number of Ordinary Shares available for issuance thereunder by an additional 1,900,000 Ordinary Shares. No other amendments were made to the Plan. On August 1, 2017, the Company's board of directors approved grants of 608 thousand RSUs and 440 thousand options. The options have an exercise price equals to USD1.85 per one ordinary share. The RSUs and/or options have a vesting period of 3 years from the commencement of the Officer's or Director's engagement, with a one-year cliff for the first one-third of the vested amount, and over 8 quarters thereafter. The exercise period is 7 years from the date of the grant. 22 thousand RSUs and 20 thousand options were fully vested at the time of the grant. The fair value of these RSUs and options at the date of the grant was measured at USD 1,326 thousand and USD 592 thousand, respectively. The Company recorded in 2019 an expense of USD 1,273 thousand (2018 - USD 719 thousand), of which USD 988 thousand (2018 - USD 660 thousand) are to key management personnel. B Other share based payment arrangements See Note 9E with regards to share based payments to service providers. C. The number and weighted average exercise prices (in USD) of share options are as follows: Weighted average exercise price Number of options 2019 2018 2017 2019 2018 2017 Outstanding on January 1 2.60 3.08 4.29 1,131,781 1,002,022 519,746 Expired during the year - 7.00 20.72 - 30,000 2,239 Granted during the year 1.32 1.59 1.85 3,622,895 159,759 484,515 Outstanding on December 31 1.71 2.60 3.08 4,754,676 1,131,781 1,002,022 Exercisable on December 31 3.21 2.95 2.83 1,093,029 873,344 708,879 The exercise price is denominated in NIS and are re-measured using historic exchange rates. The options outstanding at December 31, 2019 had an exercise price of USD 0.81- USD 6 (2018 - USD 1.59- USD 4.39, 2017 -USD 1.84 - USD 7.01), and weighted average contractual life of 5.56 years (2018 - 5.29 years, 2017 - 7.2 years). D. The number of RSUs are as follows: Number of RSUs 2019 2018 Outstanding at January 1 109,419 170,727 Granted during the year - 59,720 Vested during the year 97,910 121,028 Outstanding at December 31 11,509 109,419 E. Options to service providers were measured at the fair value of the service, when available. The fair value of the Company's share options granted to employees, directors and service providers, where fair value of service was not measurable, was measured using the binominal model, using the fair value of the traded warrants with similar terms, making certain adjustments to reflect the specific terms of the options based on the expected duration. The following assumptions were used : 2019 2018 2017 Share Price - USD 0.746 - 1.22 1.18 1.82 - 2.17 Option price - USD 0.49-1.1 0.80 3.28 - 3.82 Expected volatility (%) 99.22-113.78 105.77 80.65 - 80.91 Expected duration (years) 4.61-7 4.95 6.77 - 6.97 Dividend yield (%) - - - Risk free rate interest rate (%) 1.63%-1.95% 1.41 % 1.36 - 1.39 F. On January 3, 2018, TyrNovo granted 1,170 options of TyrNovo to certain employees. The options were fully vested at the date of grant. The exercise period is 7 years from the date of the grant. The options shall have an exercise price equals to USD 0.29 per one ordinary share. The fair value of these options at the date of the grant was measured at USD 431 thousand. The fair value of these options was measured using the binominal model, The following assumptions were used : 2018 Share Price - USD 368.39 Option price - USD 369.39 Expected volatility (%) 79.16 Expected duration (years) 7 Dividend yield (%) - Risk free rate interest rate (%) 2.4 % In 2018, the Company recorded a share-based compensation expense of USD 431 thousand, of which USD 402 thousand are to key management personnel. G. Expenses recognized in the consolidated financial statements: For the year ended December 31 2019 2018 2017 USD thousands Research and development expenses 238 546 709 General and administrative expenses 1,035 227 1,570 Other expenses - - 29 Total share-based expense recognized 1,273 773 2,308

Transactions and Balances with

Transactions and Balances with Related Parties	12 Months Ended
	Dec. 31, 2019
Disclosure of transactions between related parties [abstract]
Transactions and Balances with Related Parties	Note 11 - Transactions and Balances with Related Parties In addition to their salaries or fees, the Group also provides non-cash benefits to directors and executive officers, and contributes to a post-employment defined contribution plan on behalf of employees. Certain executive officers are entitled to termination benefits of up to 6 monthly salaries or fees. Executive officers also participate in the Group's share option programs. For further information, see Note 10 regarding share-based payments. Expenses of key management personnel: The Company recorded expenses to executive officers: For the year ended December 31 2019 2018 2017 USD thousands Short - term employee benefits 1,776 2,165 2,305 Post-employment benefits 22 16 137 Share based payments 719 574 1,669 2,517 2,755 4,111 The Company recorded expenses to directors: For the year ended December 31 2019 2018 2017 USD thousands Short - term benefits 339 268 217 Share based payments 269 86 236 608 354 453

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2019
Disclosure of contingent liabilities [abstract]
Commitments and contingent liabilities	Note 12 – Commitments and contingent liabilities A. Commitments 1. TyrNovo, has obligations to the Israel Innovation Authority (hereinafter: "IIA") with respect to grants it received from the IIA in connection with TyrNovo's technology. The requirements and restrictions for such grants are found in the Encouragement of Research, Development and Technological Innovation in Industry Law 5744-1984 and in the IIA's rules and guidelines and the terms of these grants. In general, a recipient company is obligated to pay the IIA royalties from the revenues generated from the sale of products and related services developed as a result of, a research and development program funded by the IIA (currently a yearly rate of 3% to 6%), up to the aggregate amount of the total grants received by the IIA, plus annual interest. Tyrnovo will not be required to repay the grants if it does not generate revenue. TyrNovo's technologies were developed, at least in part, with funds from IIA grants, and accordingly is obligated to pay royalties on sales of any of its IIA funded products and related services. As of December 31, 2019, the maximum royalty amount that would be payable by TyrNovo, excluding interest, is approximately NIS 5.5 million (USD 1.6 million), and as of such date, TyrNovo had not paid any royalties to the IIA. The Group does not recognize a liability for royalties because there is no reasonable assurance, as of the reporting period, that the underlying sales will occur in the future. Therefore, the financial statements do not include a liability for these royalties. 2. TyrNovo has entered into a license agreement (the "License Agreement") with Yissum Research Development company of the Hebrew University of Jerusalem Ltd. (hereafter "Yissum") dated August 15, 2013, as amended. In accordance with the License Agreement, Yissum granted the Company an exclusive license to commercialize, exploit, develop, manufacture, market, import, export, distribute, offer to sell, or sell products, that are derived from Yissum's licensed technology. In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license: (i) Royalties at a rate of three percent (3%) of net sales. (ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration. In addition, Yissum is entitled to receive an exit fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement. The consolidated financial statements do not include a liability for royalties or sublicense fees for this license agreement as there is no minimum payments and thus obligation will be recognized when the related sales will occur. B. Claims 1. In December 2015, a lawsuit and a motion to approve such lawsuit as a class action was filed against the Company and its directors by shareholders who were holding the Company's Tel Aviv Stock Exchange listed securities before the offering that took place in November 2015, claiming damages for the purported class in the motion totaling NIS 16.4 million (USD 4.3 million) due to the said offering (the "Motion"). The Company delivered its response to the court in accordance with applicable law. A preliminary hearing held by the court on September 12, 2016 and subsequently the court set a schedule for the submission by the petitioners of a motion for discovery, and any responses to such motion. Additional preliminary hearings were held during 2017. On October 24, 2017 the court issued a ruling to stay proceedings in this matter until January 15, 2018 due to the ongoing ISA Investigation (See Note 12B(3) below). At the request of the ISA, this stay was subsequently extended several times by the court. Following approval of the Enforcement Arrangement in connection with the ISA Investigation (see Note 12B(3)), the stay was lifted. An evidentiary hearing was scheduled for June 23, 2020. 2. On November 8, 2016, a shareholder of the Company submitted a request to the court in connection with the Motion to be excluded from the purported class and claiming to have independent causes of action and claims of approximately NIS 1 million (USD 262 Thousand) (the "Petition to Exclude"). The Company responded to the court as required, and, amongst other arguments, the Company noted that such shareholder cannot petition to be excluded from the purported class. The court ordered the shareholder to respond and he has done so. In May 2018 the shareholder submitted an independent lawsuit against the Company in the Haifa Magistrates Court seeking damages of approximately NIS 1.1 million (USD 306 Thousand) (the "Separate Lawsuit"). In August 2018 the Haifa Magistrates Court transferred the Separate Lawsuit to the Tel Aviv Magistrates Court. The Company is of the view that such shareholder's claims are identical to the asserted claims for damages in the Motion, and has notified the court of such and have sought a stay of proceedings pending the outcome of the Motion. A hearing on the Company's motion to dismiss the Separate Lawsuit and/or stay the proceedings has been scheduled for May 1, 2019, at which it dismissed without prejudice in May 2019. This shareholder subsequently filed a new separate claim against the Company in the Haifa District Court – Economic Division, which has since been transferred to the Tel Aviv District Court – Economic Division. In January 2020, the Tel Aviv District Court – Economic Division accepted the Company's position that the shareholder's claims are identical to the asserted claims for damages in the Motion, and entered a stay of proceedings pending the outcome of the Motion. The Company's management rejects the claims asserted in the Motion as well as in the Petition to Exclude and the Separate Lawsuit, and, in consultation with its legal advisors, believes that the likelihood of the Company not incurring any financial obligation as a result of this class action exceeds the likelihood that the Company will incur a financial obligation. Therefore, no provision for this matter was recorded in these financial statements. 3. In February 2017 the Company announced that the Israeli Securities Authority has begun a formal investigation into, amongst other matters, the Company's public disclosures in connection with the Data Monitoring Committee (DMC) appointed in connection with the Company's Phase III trial of KIT-302, the results of which were announced in December 2015, and what information regarding the DMC was disclosed publicly by Kitov. A DMC is generally an external independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing, and, in the case of the KIT-302 Phase III clinical trial, was established in order to analyze the preliminary results of the initial patient group enrolled in the clinical trial and determine the number of additional patients, if any, that Kitov might have needed to recruit in order to demonstrate statistical validity, and to meet the primary end point of the clinical trial. In February 2017, four lawsuits and motions to approve the lawsuits as a class action lawsuit (each, a "Motion"), were filed against the Company and certain of its office holders at the Tel Aviv District Court (Economic Division), and served on the Company, with each Motion relating to the above noted formal investigation by the Israeli Securities Authority (ISA) into the Company's public disclosures (the "2017 Motions"). One of these motions was subsequently withdrawn. The petitioners in one of the motions petitioned the court to dismiss the other 2 of the 2017 Motions ("Petition for Dismissal"). On December 19, 2017 the court granted the Petition for Dismissal and dismissed the other remaining 2017 Motions. The remaining motion (the "Surviving Motion") was filed against the Company, the Company's executive directors and certain of its present and former directors, by certain shareholders who are requesting to act as representatives of all shareholders of record from December 10, 2015 until February 6, 2017. The plaintiffs allege, among other things, that the Company included misleading information in its public filings which caused the class for which the plaintiffs are seeking recognition, an aggregate loss of approximately NIS 29 million (approximately USD 8 million). The Company and other defendants have not yet delivered their response to the court, and will do so in accordance with applicable law and the court's instructions. The court ordered a stay of proceedings due to the ongoing ISA Investigation. Following approval of the " Enforcement Arrangement" (see below) in connection with the ISA Investigation, the stay was lifted. On March 8, 2020 the court approved scheduling arrangement agreed to by the parties to the Surviving Motion, whereby the the petitioners in the Surviving Motion will have 45 days to submit an amended lawsuit and motion to approve the lawsuit as a class action, the respondents will have 60 days following the submission of such amended fillings to submit their responses, and the petitioners will then have an additional 30 days to respond to the respondents' filings. Under applicable Israeli law, a motion to approve a lawsuit as a class action initially needs to be approved as such by the court. Only after such approval is granted by the court, will the court proceed to the second stage of hearing the underlying claims of the class action lawsuit. The Company's management rejects the claims in all of the aforesaid Motions and class action lawsuits. At this preliminary stage the Company is unable, with any degree of certainty, to make any evaluations or any assessments with respect to the Surviving Motion as to the probability of success or the scope of potential exposure, if any. Therefore, no provision for this matter was recorded in these financial statements. On February 7, 2017, a holder of the Company's securities listed on the NASDAQ filed in the United States District Court (Southern District of New York), a federal securities class action relating to the above noted formal investigation by the ISA into the Company's public disclosures against the Company, its CEO and CFO, seeking unspecified damages and relief in connection with, amongst other things, damages alleged to have occurred due to the purchasers of the Company's securities in the Company's initial public offering in the USA on November 20, 2015, as well as in open market purchases, as a result of the Company allegedly including misleading information in its public filings. An amended complaint was filed on June 19, 2017, which complaint limited the scope of its claims as compared to the original complaint. On August 2, 2017, the Company filed a motion to dismiss the amended complaint in its entirety. In addition, on September 20, 2017, the Company filed a letter motion requesting a conference on the issue of whether this litigation should be dismissed. On September 21, 2017, the court granted the Company's request, and on November 7, 2017, the court ordered that the issues raised in the letter motion would be considered together with and supplementing the motion to dismiss. No decision was rendered on the motion to dismiss. On February 10, 2017, a holder of the Company's securities listed on the NASDAQ filed in the Superior Court of the State of California, a securities class action relating to the above noted formal investigation by the ISA into the Company's public disclosures, against the Company, its CEO and CFO and the underwriters in the Company's initial public offering in the USA on November 20, 2015, seeking unspecified damages and relief in connection with, amongst other things, damages alleged to have occurred due to the purchasers of the Company's securities in such public offering as a result of the Company allegedly including misleading information in its public filings. On March 20, 2017, a holder the Company's securities listed on the NASDAQ filed in the Superior Court of the State of California, a securities class action against the Company, its CEO and CFO and the underwriters in the Company's initial public offering in the USA on November 20, 2015, seeking unspecified damages and relief in connection with, amongst other things, damages alleged to have occurred due to the purchasers of the Company's securities in such public offering as a result of the Company allegedly including misleading information in its public filings. On April 6, 2017, the Superior Court of the State of California for the County of San Mateo entered an order consolidating the two California putative class actions. An amended complaint was filed on or about June 5, 2017. On December 15, 2017, the Company filed a motion to stay discovery pending the resolution of the ISA Investigation. Following Plaintiffs' opposition to the Company's motion on January 5, 2018 and the Company's reply in further support on January 16, 2018, the court ruled in the Company's favor after arguments on January 29, 2018 staying discovery by Plaintiffs against the Company and the individual defendants until June 1, 2018, at which point the parties are to update the court on the status of the ISA's investigation. Discovery against the underwriters continued. In June 2018 the Company entered into a Memorandum of Understanding and subsequently, in July 2018 entered into a Stipulation of Settlement with respect to the shareholder class action lawsuits pending against it. Under the terms of the proposed settlement, the purported classes in all of the actions will receive aggregate consideration of USD 2.0 million. The settlement consideration, as well as ancillary expenses, will be funded by the Company's insurance carriers, who have indicated to the Company that they have already made reserves for the settlement consideration. The settlement was approved by the court in March 2019 and has been finalized. Pursuant to the final settlement, the Company and its directors and officers are released from the claims that were asserted or could have been asserted in the Actions by class members participating in the settlement. ISA Administrative Enforcement Arrangement: On August 13, 2019, the Administrative Enforcement Committee (the "Committee") of the Israel Securities Authority ("ISA") approved an administrative enforcement agreement, titled Enforcement Arrangement ("Enforcement Arrangement"), entered into by and amongst ISA, Kitov Pharma Ltd. (the "Company" or the "Registrant"), Isaac Israel, the Company's chief executive officer, Paul Waymack, the Company's former chairman and Simcha Rock, the Company's former chief financial officer, pursuant to which the Company and each of Messrs. Israel, Waymack and Rock settled the ISA's claims that under Israeli Securities Laws the Company made negligent disclosures in a number of its historical reports filed with the ISA in 2014 and 2015, and the ISA decided to discontinue its criminal investigation and to cease all proceedings against the Company and its principals with respect to the facts set out in the Enforcement Arrangement. As part of the Enforcement Arrangement the Company shall pay a fine of NIS 1,500,000 (approximately USD 430,000), payable in 24 consecutive monthly payments. The Company, by vote of a committee consisting of independent members of the Board of Directors, and the above mentioned principals, agreed to the Enforcement Arrangement with the ISA.

Revenues

Revenues	12 Months Ended
	Dec. 31, 2019
Revenue [abstract]
Revenues	Note 13 - Revenues Revenues recorded are from upfront payments of license agreements. Such revenues in 2019 are from a customer in the U.S and in each of 2018 and 2017 from two customers in the far-east.

Research and Development Expens

Research and Development Expenses	12 Months Ended
	Dec. 31, 2019
Research and Development Expenses [Abstract]
Research and Development Expenses	Note 14 - Research and Development Expenses For the year ended December 31 2019 2018 2017 USD thousands Salaries, wages and related expenses 1,012 933 969 Share-based payments (see also Note 10) 238 546 709 Service providers (*) 1,424 3,789 2,962 2,674 5,268 4,640 (*) The Company has determined that it acts as an agent for certain transactions, see Note 3I. Accordingly, the Company recorded USD 532 thousand as an offset of R&D costs. Receivables and payables regarding such transactions are recorded on a gross basis (see Notes 7 and 8, respectively).

Sales, General and Administrati

Sales, General and Administrative Expenses	12 Months Ended
	Dec. 31, 2019
General and Administrative Expenses [Abstract]
Sales, General and Administrative Expenses	Note 15 - Sales, General and Administrative Expenses A. For the year ended December 31 2019 2018 2017 USD thousands Employees and officers compensation 1,445 1,733 1,984 Share-based payments (see also Note 10) 657 87 1,224 Legal fees in connection with ISA investigation and class action lawsuits (see also Note 12B) 356 690 893 Other professional consulting 900 1,525 1,306 Board member remuneration and insurance 622 470 505 Board member share-based payments 269 86 47 FDA Fee 946 - - ISA settlement (see also Note 12B) 387 - - Rent and office maintenance 80 243 196 Travel 144 143 131 Car expenses 38 85 64 Depreciation 178 7 4 Other 56 126 43 6,078 5,195 6,397 B. The Consolidated Statements of Operations for the year ended December 31, 2019, include refunds from the insurance company in respect of legal expenses in the amount of USD 596 thousand, and for December 31, 2018, amount of USD 743 thousand.

Other Expenses (Income)

Other Expenses (Income)	12 Months Ended
	Dec. 31, 2019
Other Expenses (Income) [Abstract]
Other Expenses (Income)	Note 16 - Other Expenses (Income) During 2017 the Company recorded an amount of USD 1,029 thousand in its consolidated financial statements under Other Expenses, with regards to rights granted to Taoz as part of the Company's settlement with Taoz, regarding the acquisition of TyrNovo, See also Note 5B. During 2018, the Company acquired Taoz's holdings in TyrNovo. As part of the agreement with Taoz, it waived the rights described in Note 5B, and the Company recorded an amount of USD 894 thousand under Other Income, see also Note 5C .

Finance Expense (Income)

Finance Expense (Income)	12 Months Ended
	Dec. 31, 2019
Finance Expense (Income) [Abstract]
Finance Expense (Income)	Note 17 - Finance Expense (Income) For the year ended December 31 2019 2018 2017 USD thousands Income (expenses) in respect of derivatives, net (*) (1,509 ) (2,740 ) 1,049 (*) The derivatives are related mainly to the fair value adjustments of warrants. The 2019, 2018 and 2017 warrants included a cashless exercise feature, which expired on September 16, 2019, September 12, 2019 and August 8, 2018, respectively, when the Company filed a registration statement with the SEC, registering the shares that will derive from future exercise of these warrants. See also Note 20B. For the year ended December 31 2019 2018 2017 USD thousands Finance expense Fees and interest expense 81 9 26 Loss from exchange rate differences, net 100 106 - Payment to Taoz, see Note 5C - 160 - Warrant issuance costs - 301 - 181 576 26 For the year ended December 31 2019 2018 2017 USD thousands Finance income Income from exchange rate differences, net - - (22 ) Interest income from short term deposits (151 ) (93 ) (106 ) (151 ) (93 ) (128 )

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2019
Taxes on Income [Abstract]
Taxes on Income	Note 18 - Taxes on Income A. Corporate tax rate The tax rate applicable to the Group for 2019 and 2018 is 23%. The tax rate in 2017 was 24%. B. Carry-forward losses The Company and its subsidiaries incurred losses through 2019, which are not expected to be utilized in the foreseeable future. Therefore, the Group did not record current taxes or deferred taxes. In 2019, the main reconciling item from the statutory tax rate of the Company (23%, representing theoretical tax benefit of approximately USD 1.3 million) to the effective tax rate (0%) is the fact that deferred taxes were not created in respect of carry forward tax losses. The carry-forward loss for tax purposes for the Company and its subsidiaries, and the unrecognized research and development expenses, amounts to USD 21 million as of December 31, 2019 (2018 – USD 33.1 million, 2017 – USD 28.2 million). C. Tax assessments The Company's tax assessments are deemed finalized through the end of 2017, pursuant to section 145 of the Israeli Income Tax Ordinance. The subsidiary's tax assessments are deemed finalized through the end of 2014, pursuant to section 145 of the Israeli Income Tax Ordinance. During 2019, the Company's tax assessments for Kitov Pharma Ltd. for the tax years of 2014 - 2017 were finalized. Following the tax assessments, the Company was required to pay an amount of approximately 250 USD thousands which were recorded as an expense in 2019.

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2019
Employee Benefits [Abstract]
Employee benefits	Note 19 - Employee benefits A. Employee benefits include post-employment benefits and short term benefits. Balances include: For the Year ended December 31 2019 2018 USD thousands USD thousands Short-term benefits 365 136 Post-employment benefits 285 405 B. Post-employment benefit plans – defined contribution plan The Company has a defined contribution plan in respect of the Company's liability in respect of its employees who are subject to Section 14 of the Severance Pay Law – 1963. For the Year ended December 31 2019 2018 2017 USD thousands USD thousands USD thousands Amount recognized as expense in respect of defined contribution plan 136 95 52 C. Certain of the Company's senior executives are entitled to annual and special bonuses under the terms of their employment and consulting agreements. These bonuses will become due upon the achievement of certain goals or agreements for the commercialization of the Company's products. These consolidated financial statements include bonuses in the amount of USD 462 thousand for the year ended December 31, 2019, and USD 777 thousand for the year ended December 31, 2018. D. Certain of the Company's senior executives are entitled to benefits upon termination of employment under the terms of their employment and consulting agreements, see Note 11 on related parties. These benefits are measured based on the time of service and their monthly pay and the expected term of their employment. These consolidated financial statements include a liability due to these grants of USD 285 thousand and USD 405 thousand, as of December 31, 2019 and 2018, respectively.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2019
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments	Note 20 - Financial Instruments Framework for risk management The Board of Directors has overall responsibility for the establishment and oversight of the Group's risk management framework. The Group's risk management practice was formulated to identify and analyze the risks that the Group faces, to set appropriate limits for the risks and controls, and to monitor the risks and their compliance with the limits. The risk policy and risk management methods are reviewed regularly to reflect changes in market conditions and in the Group's operations. The Group acts to develop an effective control environment in which all employees understand their roles and commitment. The Group Audit Committee oversees how management monitors compliance with the Group's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Group. The Group Audit Committee is assisted in its oversight role by Internal Audit. Internal Audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the Audit Committee. A. Risk management 1. Credit risk Credit risk is the risk of financial loss to the Group if a debtor or counterparty to a financial instrument fails to meet its contractual obligations, and arises mainly from the Company's receivables. The Group restricts exposure to credit risk by investing only in bank deposits. The Group held cash and cash equivalents and short-term deposits of USD 4,395 thousand at December 31, 2019 (2018 – USD 6,684). These are held with banks, which are rated A2, based on Moody's Rating Agency ratings. The short-term deposits, mainly in USD, bear fixed interest ranging between 0.02% - 2.97%. The carrying amount of cash and cash equivalents and short-term deposits approximate their fair value. 2. Market risk Market risk is the risk that changes in market prices, such as foreign currency exchange rates, the CPI, interest rates and the prices of equity instruments, will influence the Group's results or the value of its holdings in financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing returns. Currency risk The Group is exposed to currency risk mainly for cash and purchases for research and development expenses that are denominated in dollars and euros. Therefore, the Group is exposed to exchange rate fluctuations in these currencies against the NIS and takes steps to reduce the currency risk by maintaining its liquid resources in accordance with its future needs. Set forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2019: Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 2 5 106 (5 ) (2 ) Other current assets 9 22 440 (22 ) (9 ) Accounts payable (18 ) (45 ) (903 ) 45 18 Other payables (20 ) (49 ) (985 ) 49 20 Post-employment benefit liabilities (2 ) (5 ) (101 ) 5 2 Total income (loss) (29 ) (72 ) 72 29 B. Financial instruments measured at fair value: 1. A loan of USD 2 million to FamWave was accounted for as a financial asset at fair value (see Note 1E for further information). 2. In September 2019, the Company registered the warrants issued in 2018 and 2019 and therefore they were reclassified from financial liabilities to equity in their fair value using Black & Scholes valuation method. 3. Fair value hierarchy of financial instruments measured at fair value: December 31, 2019 Level 1 Level 2 Level 3 Total USD thousands Financial assets Loan - - 2,000 2,000 December 31, 2018 Level 1 Level 2 Level 3 Total USD thousands Financial liabilities Warrants (see Note 9D(2)) - - 554 554 Details regarding fair value measurement at Level 3: Financial instrument Valuation method for determining fair value Significant unobservable inputs For the year ended December 31, 2019 Warrants Black - Scholes expected term 4.02-4.83 years expected volatility 99 % annual risk free interest 1.95 % dividend yield 0 % For the year ended December 31, 2018 Warrants Black - Scholes expected term 4.9 years expected volatility 97.29 % annual risk free interest 2.51 % dividend yield 0 % 4. The recoverable amount of the in-process research and development (hereinafter – "intangible asset") was based on its value in use and was determined by discounting the future cash flows to be generated from it. The recoverable amount of the intangible asset exceeds it's carrying amount, thus no impairment loss was recognized. Key assumptions used in calculation of recoverable amount: Discount rate The discount rate used for calculating intangible asset recoverable amount is 20%, taking into consideration the risk associated in drug candidates at this stage of development.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 21 - Subsequent Events 1. On March 14, 2019 the Company signed an agreement to acquire 100% of FameWave Ltd, a privately held biopharmaceutical Company developing CM-24, ("FameWave") from its shareholders in exchange for USD 10 million worth of its newly issued ADSs with a long-term lock-up period, priced at USD 1.23 per ADS, plus 50% warrant coverage based on an exercise price of USD 1.98 per ADS with a 4-year term. In addition, the Company provided a loan to FameWave of up to approximately USD 2 million to be paid to cCAM BioTherapeutics Ltd., a wholly owned subsidiary of Merck Sharp and Dohme Corp., known as "MSD" in Israel, which discovered CM-24, or to repay certain loans provided by FameWave's shareholders. The acquisition closed in January 7, 2020. Under the terms of the agreement, OrbiMed, Pontifax and Arkin Holdings, leading life-science focused investment funds, are exchanging their shares in FameWave for Kitov ADSs and warrants, and investing USD 3.5 million in Kitov in exchange for additional newly issued ADSs of Kitov. As of January 7, 2020, OrbiMed, Pontifax and Arkin Holdings each hold approximately 11% of Kitov's shares on a non-diluted basis. 2. In March 2020, in a public offering on the NASDAQ, the Company raised a gross amount of USD 6.0 million (approximately USD 5.2 million net of placement agent fees and other offering related expenses). In this public offering, the Company issued 9,620,000 ADSs and 10,380,000 pre-funded warrants, 20,000,000 warrants to purchase 20,000,000 ADSs. Each pre-funded warrant is exercisable until March, 2035 at an exercise price of USD 0.0001 and each warrant is exercisable until March, 2025 at an exercise price of USD 0.325 per ADS. In addition, the placement agent in this offering was granted 1,400,000 warrants to purchase 1,400,000 ADSs exercisable until March, 2025 at an exercise price of USD 0.375 per ADS. The Company will also issue 250,000 ADS in a private placement to the previous placement agent in this transaction. 3. In December 2019, a strain of coronavirus was reported to have surfaced in Wuhan, China, and in 2020 has reached multiple other countries, resulting in government-imposed quarantines, travel restrictions and other public health safety measures in China, the USA, Israel, and other affected countries. The various precautionary measures taken by many governmental authorities around the world in order to limit the spread of the Coronavirus, which has affected and could have an adverse effect on the global markets and its economy, including on the availability and pricing of employees, resources, materials, manufacturing and delivery efforts and other aspects of the global economy. Therefore, the Coronavirus could disrupt production and cause delays in the supply and delivery of products used in our operations, may affect our operation, including the conduct of clinical studies, or the ability of regulatory bodies to grant approvals or supervise our candidates and products, may further divert the attention and efforts of the medical community to coping with the Coronavirus and disrupt the marketplace in which we operate and may have a material adverse effects on our operations. As of the date of March 16, 2020 we cannot estimate the effect of this development, if any.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Significant Accounting Policies [Abstract]
Basis of consolidation	A. Basis of consolidation 1. Business combination The Group accounts for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognized in profit or loss immediately. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities. The consideration transferred does not include amounts related to the settlement of pre-existing relationships. Such amounts are generally recognized in profit or loss. 2. Subsidiaries Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The consolidated financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. 3. Non-controlling interests Non-controlling interests are measured initially at their proportionate share of the acquiree’s identifiable net assets at the date of acquisition. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. 4. Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements.
Foreign currency transactions	B. Foreign currency transactions Transactions in foreign currency are translated to the functional currency of the Group at exchange rates as of the transaction dates. Monetary assets and liabilities denominated in foreign currency as of the reporting date are translated into the functional currency at the exchange rate as of the said date. Exchange rate differences with respect to monetary items are the differences between the amortized cost in the functional currency as of the start of the year, adjusted for the effective interest during the year, and the amortized cost in foreign currency, translated at the exchange rate as of the end of the year. Non-monetary items denominated in foreign currency and measured at historical cost, are translated using the exchange rate as of the transaction date. Exchange rate differences arising from translation into the functional currency are recognized on the statement of operations as financial expenses.
Financial instruments	C. Financial instruments 1. Non-Derivative financial instruments a. Non-derivative financial assets – policy applicable as from January 1, 2018 Initial recognition and measurement of financial assets The Group initially recognizes trade receivables and debt instruments issued on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition to one of the following measurement categories: assets at amortized cost; assets at fair value through other comprehensive income – investments in debt instruments; assets at fair value through other comprehensive income – investments in equity instruments; or assets at fair value through profit or loss. Financial assets are not reclassified in subsequent periods unless, and only if, the Group changes its business model for the management of financial debt assets, in which case the affected financial debt assets are reclassified at the beginning of the period following the change in the business model. b. Non-derivative financial assets – policy applicable before January 1, 2018 Initial recognition and measurement of financial assets The Group initially recognizes receivables and deposits on the date that they are created. All other financial assets acquired in a regular way purchase, are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument, meaning on the date the Group undertook to purchase or sell the asset. Non-derivative financial assets include: cash and cash equivalents, short term deposits and other receivables. Cash and cash equivalents include cash balances available for immediate use and call deposits. Cash equivalents include short-term highly liquid investments (with original maturities of three months or less) that are readily convertible into known amounts of cash and are exposed to insignificant risks of change in value. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. c. Non-derivative financial liabilities Non-derivative financial liabilities include: accounts payables and other payables. Initial recognition of financial liabilities The Group initially recognizes debt securities issued on the date that they originated. All other financial liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Subsequent measurement of financial liabilities Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Financial liabilities are designated at fair value through profit or loss if the Group manages such liabilities and their performance is assessed based on their fair value in accordance with the Group’s documented risk management strategy, providing that the designation is intended to prevent an accounting mismatch, or the liability is a combined instrument including an embedded derivative. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled or transferred to equity. d. Derivative financial liabilities The Group holds derivative financial instruments that do not serve for hedging purposes. Measurement of derivative financial instruments Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are accounted for as described below. The changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these derivatives is based on an evaluation, and classified as level 3.
Intangible assets	D. Intangible assets 1. Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involve also plans or designs for the production of new or substantially improved products and processes. Development expenditure are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are recognized in profit and loss as expense. 2. Other intangible assets Other intangible assets, including in-process research and development in respect of the Company’s acquisition of TyrNovo (see also Note 5), which have infinite useful lives, are measured at cost less accumulated impairment losses. 3. Amortization The Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether events and circumstances continue to support the decision that the intangible asset has an indefinite useful life. 4. Timing of impairment testing Once a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of each cash generating unit that contains goodwill, or intangible assets that have indefinite useful lives or are unavailable for use.
Loss per share	E. Loss per share The Group presents loss per share data for its ordinary share capital. Loss per share is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding during the period.
Employee benefits	F. Employee benefits The Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance and pension companies, and they are classified as defined contribution plans and as defined benefit plans. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Other long-term employee benefits The Group’s net obligation in respect of long-term employee benefits plans is calculated separately for each plan by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets.
Share-based payment transactions	G. Share-based payment transactions The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and non-market performance conditions at the vesting date.
Provisions	H. Provisions A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.
Revenue	I. Revenue The Group recognizes revenue from upfront and milestone payments at the point in time the milestone criteria is met and collectability is probable. The revenue is measured according to the amount of the consideration to which the Group expects to be entitled. Identifying the contract The Group accounts for a contract with a customer only when the following conditions are met: (a) The parties to the contract have approved the contract (in writing, orally or according to other customary business practices) and they are committed to satisfying the obligations attributable to them; (b) The Group can identify the rights of each party in relation to the goods or services that will be transferred; (c) The Group can identify the payment terms for the goods or services that will be transferred; (d) The contract has a commercial substance (i.e. the risk, timing and amount of the entity’s future cash flows are expected to change as a result of the contract); and (e) It is probable that the consideration, to which the Group is entitled to in exchange for the goods or services transferred to the customer, will be collected. For the purpose of section (e) the Group examines, inter alia, the percentage of the advance payments received and the spread of the contractual payments, past experience with the customer and the status and existence of sufficient collateral. If a contract with a customer does not meet all of the above criteria, consideration received from the customer is recognized as a liability until the criteria are met or when one of the following events occurs: the Group has no remaining obligations to transfer goods or services to the customer and any consideration promised by the customer has been received and cannot be returned; or the contract has been terminated and the consideration received from the customer cannot be refunded. Identifying performance obligations On the contract’s inception date the Group assesses the goods or services promised in the contract with the customer and identifies as a performance obligation any promise to transfer to the customer one of the following: (a) Goods or services (or a bundle of goods or services) that are distinct; or (b) A series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. The Group identifies goods or services promised to the customer as being distinct when the customer can benefit from the goods or services on their own or in conjunction with other readily available resources and the Group’s promise to transfer the goods or services to the customer is separately identifiable from other promises in the contract. In order to examine whether a promise to transfer goods or services is separately identifiable, the Group examines whether it is providing a significant service of integrating the goods or services with other goods or services promised in the contract into one integrated outcome that is the purpose of the contract. Determining the transaction price The transaction price is the amount of the consideration to which the Group expects to be entitled in exchange for the license and commercialization agreement. The Group takes into account the effects of all the following elements when determining the transaction price: variable consideration, the existence of a significant financing component, non-cash consideration, and consideration payable to the customer. Variable consideration The Group includes variable consideration, or part of it, in the transaction price only when it is highly probable that its inclusion will not result in a significant revenue reversal in the future when the uncertainty has been subsequently resolved. At the end of each reporting period and if necessary, the Group revises the amount of the variable consideration included in the transaction price. Right to use and right to access To determine whether the Group’s promise to grant a license provides a customer with either a right to access the Group’s IP or a right-to-use the Group’s IP, the Group considers whether a customer can direct the use of, and obtain substantially all of the remaining benefits from, a license at the point in time at which the license is granted. A license is considered a “right-to-use” license when the customer maintains control of the IP upon its transfer. However, if the grantor of the license maintains involvement with the IP after its transfer, and the customer cannot direct the use of, and obtain substantially all of the remaining benefits from the license, then the license is considered a right-to-access license. The license granted by the Company, which relates to its product is granted to a third party which can obtain direct use of, and substantially all of the remaining benefits from the license at the point in time at which the license is granted. The Group will not continue to be involved in any activities that significantly affect the IP at the specific territory. Therefore recognized the license granted as right-to-use license. Principal or agent When another party is involved in providing goods or services to the customer, the Group examines whether the nature of its promise is a performance obligation to provide the defined goods or services itself, which means the Group is a principal and therefore recognizes revenue in the gross amount of the consideration, or to arrange that another party provide the goods or services which means the Group is an agent and therefore recognizes revenue in the amount of the net commission. The Group engaged with a third party to manufacture its products for the Group’s customer ("the Manufacturing Agreement"). The Group is a principal when it controls the promised goods or services before their transfer to the customer. Indicators that the Group controls the goods or services before their transfer to the customer include, inter alia, as follows: the Group is the primary obligor for fulfilling the promises in the contract; the Group has inventory risk before the goods or services are transferred to the customer; and the Group has discretion in setting the prices of the goods or services. The above indicates that in the Manufacturing Agreement the Group is an agent and therefore it recognizes such revenues on a net basis. Contract modifications A contract modification is a change in the scope or price (or both) of a contract that was approved by the parties to the contract. A contract modification can be approved in writing, orally or be implied by customary business practices. A contract modification can take place also when the parties to the contract have a disagreement regarding the scope or price (or both) of the modification or when the parties have approved the modification in scope of the contract but have not yet agreed on the corresponding price modification. The Group accounts for a contract modification as an adjustment of the existing contract since the remaining goods or services after the contract modification are not distinct and therefore constitute a part of one performance obligation that is partially satisfied on the date of the contract modification. The effect of the modification on the transaction price and on the rate of progress towards full satisfaction of the performance obligation is recognized as an adjustment to revenues (increase or decrease) on the date of the contract modification, meaning on a catch-up basis. Royalties The Company recognizes revenue for sales-based royalties promised in exchange for a license of intellectual property when the later of the following events occurs: (a) the subsequent sale occurs; or (b) the performance obligation to which some or all of the sales-based royalties has been satisfied. The Company has yet to recognize revenues from royalties.
Financing income and expense	J. Financing income and expense Finance income comprises changes in the fair value of the financial liability through profit and loss, and income from short term deposits. Finance expenses include loss from exchange rate differences. Interest expense is recognized, using the effective interest method. In the statements of cash flows, interest received is presented as part of cash flows from investing activities and interest paid is presented as part of cash flows from financing activities.
Equity	K. Equity Incremental costs directly attributable to an expected issuance of an instrument that will be classified as equity are recognized as an asset in deferred expenses in the statement of financial position. The costs are deducted from the equity upon the initial recognition of the equity instruments, or are expensed as financing expenses in the statement of operations when the issuance is no longer expected to take place.
Issuance of units of securities	L. Issuance of units of securities The consideration received from the issuance of units of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is allocated to equity. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described above.
Income tax expense	M. Income tax expense Income tax comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that they relate to a business combination, or are recognized directly in equity or in other comprehensive income to the extent they relate to items recognized directly in equity or in other comprehensive income. Current taxes Current tax is the expected tax payable (or receivable) on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date. Current taxes also include taxes in respect of prior years and any tax arising from dividends. Deferred taxes A deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets that were not recognized are reevaluated at each reporting date and recognized if it has become probable that future taxable profits will be available against which they can be utilized.
Leases	N. Leases Policy applicable as from January 1, 2019 Determining whether an arrangement contains a lease On the inception date of the lease, the Group determines whether the arrangement is a lease or contains a lease, while examining if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. In its assessment of whether an arrangement conveys the right to control the use of an identified asset, the Group assesses whether it has the following two rights throughout the lease term: (a) The right to obtain substantially all the economic benefits from use of the identified asset; and (b) The right to direct the identified asset's use. For lease contracts that contain non-lease components, such as services or maintenance, that are related to a lease component, the Group elected not to separate non-lease components from lease components and instead accounting for all the lease components and related non-lease components as a single lease component. Leased assets and lease liabilities Contracts that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these payments do not include certain variable lease payments), and concurrently recognizes a right-of-use asset at the same amount of the lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease. Since the interest rate implicit in the Group's leases is not readily determinable, the incremental borrowing rate of the lessee is used. Subsequent to initial recognition, the right-of-use asset is accounted for using the cost model, and depreciated over the shorter of the lease term or useful life of the asset. The Group has elected to apply the practical expedient by which short-term leases of up to one year and/or leases in which the underlying asset has a low value, are accounted for such that lease payments are recognized in profit or loss on a straight-line basis, over the lease term, without recognizing an asset and/or liability in the statement of financial position. The lease term The lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably certain that the lessee will or will not exercise the option, respectively. Variable lease payments Variable lease payments that depend on an index or a rate, are initially measured using the index or rate existing at the commencement of the lease and are included in the measurement of the lease liability. When the cash flows of future lease payments change as the result of a change in an index or a rate, the balance of the liability is adjusted against the right-of-use asset. Other variable lease payments that are not included in the measurement of the lease liability are recognized in profit or loss in the period in which the event or condition that triggers payment occurs. Depreciation of right-of-use asset After lease commencement, a right-of-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over the useful life or contractual lease period, whichever earlier, as follows: ● Buildings 2 years ● Motor Vehicles 2-3 years Policy applicable before January 1, 2019 Determining whether an arrangement contains a lease At inception or upon reassessment of an arrangement, the Group determines whether such an arrangement is or contains a lease. An arrangement is a lease or contains a lease if the following two criteria are met: ● The fulfillment of the arrangement is dependent on the use of a specific asset or assets; and ● The arrangement contains rights to use the asset. At inception or upon reassessment of the arrangement, the Group separates payments and other consideration required by such an arrangement into those for the lease and those for other elements on the basis of their relative fair values. If the Group concludes for a finance lease that it is impracticable to separate the payments reliably, an asset and a liability are recognized at an amount equal to the fair value of the underlying asset. Subsequently the liability is reduced as payments are made and an imputed finance charge on the liability is recognized using the buyer's incremental borrowing rate. Other leases are classified as operating leases, and the leased assets are not recognized on the Group's statement of financial position. Lease payments Payments made under operating leases, other than conditional lease payments, are recognized in profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease expense on a straight-line basis, over the term of the lease. Minimum lease payments made under operating leases are recognized in profit or loss as incurred.
New standards and interpretations not yet adopted	O. New standards and interpretations not yet adopted (1) IAS 1 Presentation of Financial Statements Amendment to IAS 1, Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current The Amendment replaces certain classification requirements for current or non-current liabilities. Thus, for example, according to the Amendment, a liability will be classified as non-current when the entity has the right to defer settlement for at least 12 months after the reporting period, and it "has substance" and is in existence at the end of the reporting period. A right is in existence at the end of the reporting period only if the entity complies with conditions for deferring settlement at that date. Furthermore, the Amendment clarifies that the conversion option of a liability will affect its classification as current or non-current, other than when the conversion option is recognized as equity. The Amendment is effective for reporting periods beginning on or after January 1, 2022 and is applicable retrospectively, including an amendment to comparative data. The Group is examining the effects of the Amendment on the consolidated financial statements with no plans for early adoption. (2) Amendment to IFRS 3, Business Combinations The Amendment clarifies whether a transaction to acquire an operation is the acquisition of a "business" or an asset. For the purpose of this examination, the Amendment added an optional concentration test so that if substantially all of the fair value of the acquired assets is concentrated in a single identifiable asset or a group of similar identifiable assets, the acquisition will be of an asset. In addition, the minimum requirements for definition as a business have been clarified, such as for example the requirement that the acquired processes be substantive so that in order for it to be a business, the operation shall include at least one input element and one substantive process, which together significantly contribute to the ability to create outputs. Furthermore, the Amendment narrows the reference to the outputs element required in order to meet the definition of a business and added examples illustrating the aforesaid examination The Amendment is effective for transactions to acquire an asset or business for which the acquisition date is in annual periods beginning on or after January 1, 2020, with earlier application being permitted. In the opinion of the Group, application of the Amendment will may have a material effect on the accounting treatment of future acquisitions of operations.

Basis of Preparation of the C_2

Basis of Preparation of the Consolidated Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2019
Basis of Preparation of the Financial Statements [Abstract]
Schedule of changes in exchange rates	Representative exchange rate of USD (NIS/USD 1) Date of consolidated financial statements: December 31, 2019 3.456 December 31, 2018 3.748 December 31, 2017 3.467 Changes in exchange rates for the year ended: % December 31, 2019 (7.8 ) December 31, 2018 8.1 December 31, 2017 (9.8 )

Operating Segments (Tables)

Operating Segments (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of operating segments [abstract]
Schedule of segment reporting information by segment	For the year ended December 31, 2019 Pain and Hypertension Oncology Total reportable segments Reconciliations (*) Total consolidated USD in thousands Revenues 1,000 - 1,000 - 1,000 Research and development expenses 395 2,041 2,436 238 2,674 Operating loss 3,068 2,815 5,883 1,273 7,156 Finance income, net (1,479 ) Tax Expenses 216 Loss for the year 5,893 For the year ended December 31, 2018 Pain and Hypertension Oncology Total reportable segments Reconciliations (*) Total consolidated USD in thousands Revenues 1,000 - 1,000 - 1,000 Research and development expenses 2,185 2,537 4,722 546 5,268 Operating loss 4,730 3,217 7,947 (121 ) 7,826 Finance income, net (2,257 ) Loss for the year 5,569 For the year ended December 31, 2017 Pain and Hypertension Oncology Total reportable segments Reconciliations (*) Total consolidated USD in thousands Revenues 100 - 100 - 100 Research and development expenses 2,603 1,328 3,931 709 4,640 Operating loss 6,674 1,951 8,625 3,341 11,966 Finance income, net 947 Loss for the year 12,913 (*) Includes employees share based expenses and other expenses/income related to rights granted to Taoz.

Subsidiary (Tables)

Subsidiary (Tables)	12 Months Ended
	Dec. 31, 2019
Subsidiary [Abstract]
Schedule of acquisition date fair value of each major class of consideration	USD thousands Cash 2,000 Equity instruments issued (564,625 Ordinary Shares) (1) 1,800 Assignment of loan to the Company (101 ) Total consideration transferred 3,699 (1) The fair value of the Ordinary Shares issued was based on the listed share price of the Group on January 11, 2017 of approximately USD 3.19 per share.
Schedule of recognized amounts of assets acquired and liabilities assumed at the date of acquisition	USD thousands Current assets 21 Fixed assets, net 3 Intangible assets (2) 6,172 Short-term credit from bank (16 ) Trade payables (123 ) Other payables (212 ) Long-term related parties (130 ) Total net identifiable assets 5,715 (2) In-process research and development
Schedule of condensed information regarding TyrNovo	Incorporated and Group's ownership equity TyrNovo Ltd. Israel 98.47 %

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2019
Cash and cash equivalents [abstract]
Schedule of cash and cash equivalents	As of December 31 2019 2018 USD thousands Balance in USD 4,279 4,410 Balance in other currencies 106 753 Total cash and cash equivalents 4,385 5,163

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Other Current Assets [Abstract]
Schedule of other current assets	As of December 31 2019 2018 USD thousands Receivables, see Note 14 1,493 - Government authorities 182 81 Reimbursement of legal fees receivable - 743 Prepaid fee to the Food and Drug Administration - 930 Prepaid expenses and other receivables 232 76 Total other current assets 1,907 1,830

Other Payables (Tables)

Other Payables (Tables)	12 Months Ended
	Dec. 31, 2019
Trade and other payables [abstract]
Schedule of other payables	As of December 31 2019 2018 USD thousands Contract liabilities, see Note 14 961 - Due to related parties - payroll related 587 910 Due to GHP (Note 5A) - 167 Accrued expenses 255 852 Government authorities 36 65 Payroll related payables 267 61 2,106 2,055

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Changes in equity [abstract]
Schedule of company's share capital	As of December 31 As of December 31 Number of shares in thousands Authorized Issued Authorized Issued Ordinary shares, no par value 250,000 19,564 250,000 16,099 Class A preferred shares, no par value 10,000 - 10,000 - Class B preferred shares, no par value 10,000 - 10,000 - Class C preferred shares, no par value 10,000 - 10,000 - Class D preferred shares, no par value 10,000 - 10,000 - Class E preferred shares, no par value 10,000 - 10,000 -
Schedule of changes in share capital during the year	For the year ended December 31 2019 2018 2017 Number of shares in thousands Issued as at January 1 16,009 11,222 7,662 Issuance of ADSs (See D below) 3,429 3,260 2,432 Issuance of shares (See Note 5) - 799 565 Vesting of RSUs 97 121 563 Exercise of warrants 29 607 - Issued as at December 31 19,564 16,009 11,222
Schedule of information relating to subsidiary that has material non-controlling interests	December 31 December 31 TyrNovo Ltd. in USD thousand Non-controlling interests percentage 1.53 % 2.4 % Non-current assets 24 9 Current assets 192 415 Current liabilities (646 ) (4,120 ) Net assets (430 ) (3,696 ) Net assets attributable to non-controlling interests (7 ) (89 ) Loss for the year 2,847 3,688 Loss allocated to non-controlling interests 43 369

Share-based Payment Arrangeme_2

Share-based Payment Arrangements (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of range of exercise prices of outstanding share options [line items]
Summary of number and weighted average exercise prices (in USD) of share options	Weighted average exercise price Number of options 2019 2018 2017 2019 2018 2017 Outstanding on January 1 2.60 3.08 4.29 1,131,781 1,002,022 519,746 Expired during the year - 7.00 20.72 - 30,000 2,239 Granted during the year 1.32 1.59 1.85 3,622,895 159,759 484,515 Outstanding on December 31 1.71 2.60 3.08 4,754,676 1,131,781 1,002,022 Exercisable on December 31 3.21 2.95 2.83 1,093,029 873,344 708,879
Summary of number of RSUs	Number of RSUs 2019 2018 Outstanding at January 1 109,419 170,727 Granted during the year - 59,720 Vested during the year 97,910 121,028 Outstanding at December 31 11,509 109,419
Summary of options to service providers were measured at the fair value of the service	2019 2018 2017 Share Price - USD 0.746 - 1.22 1.18 1.82 - 2.17 Option price - USD 0.49-1.1 0.80 3.28 - 3.82 Expected volatility (%) 99.22-113.78 105.77 80.65 - 80.91 Expected duration (years) 4.61-7 4.95 6.77 - 6.97 Dividend yield (%) - - - Risk free rate interest rate (%) 1.63%-1.95% 1.41 % 1.36 - 1.39
Summary of share based expenses recognized	For the year ended December 31 2019 2018 2017 USD thousands Research and development expenses 238 546 709 General and administrative expenses 1,035 227 1,570 Other expenses - - 29 Total share-based expense recognized 1,273 773 2,308
Option pricing model [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Summary of options to service providers were measured at the fair value of the service	2018 Share Price - USD 368.39 Option price - USD 369.39 Expected volatility (%) 79.16 Expected duration (years) 7 Dividend yield (%) - Risk free rate interest rate (%) 2.4 %

Transactions and Balances wit_2

Transactions and Balances with Related Parties (Tables)	12 Months Ended
	Dec. 31, 2019
Chief Executives Officer [Member]
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Schedule of payments to key management	For the year ended December 31 2019 2018 2017 USD thousands Short - term employee benefits 1,776 2,165 2,305 Post-employment benefits 22 16 137 Share based payments 719 574 1,669 2,517 2,755 4,111
Directors [Member]
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Schedule of payments to key management	For the year ended December 31 2019 2018 2017 USD thousands Short - term benefits 339 268 217 Share based payments 269 86 236 608 354 453

Research and Development Expe_2

Research and Development Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Research and Development Expenses [Abstract]
Schedule of research and development expenses	For the year ended December 31 2019 2018 2017 USD thousands Salaries, wages and related expenses 1,012 933 969 Share-based payments (see also Note 10) 238 546 709 Service providers (*) 1,424 3,789 2,962 2,674 5,268 4,640 (*) The Company has determined that it acts as an agent for certain transactions, see Note 3I. Accordingly, the Company recorded USD 532 thousand as an offset of R&D costs. Receivables and payables regarding such transactions are recorded on a gross basis (see Notes 7 and 8, respectively).

Sales, General and Administra_2

Sales, General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
General and Administrative Expenses [Abstract]
Schedule of of general and administrative expenses	For the year ended December 31 2019 2018 2017 USD thousands Employees and officers compensation 1,445 1,733 1,984 Share-based payments (see also Note 10) 657 87 1,224 Legal fees in connection with ISA investigation and class action lawsuits (see also Note 12B) 356 690 893 Other professional consulting 900 1,525 1,306 Board member remuneration and insurance 622 470 505 Board member share-based payments 269 86 47 FDA Fee 946 - - ISA settlement (see also Note 12B) 387 - - Rent and office maintenance 80 243 196 Travel 144 143 131 Car expenses 38 85 64 Depreciation 178 7 4 Other 56 126 43 6,078 5,195 6,397

Finance Expense (Income) (Table

Finance Expense (Income) (Tables)	12 Months Ended
	Dec. 31, 2019
Finance Expense (Income) [Abstract]
Schedule of net change in fair value of derivatives	For the year ended December 31 2019 2018 2017 USD thousands Income (expenses) in respect of derivatives, net (*) (1,509 ) (2,740 ) 1,049 (*) The derivatives are related mainly to the fair value adjustments of warrants. The 2019, 2018 and 2017 warrants included a cashless exercise feature, which expired on September 16, 2019, September 12, 2019 and August 8, 2018, respectively, when the Company filed a registration statement with the SEC, registering the shares that will derive from future exercise of these warrants. See also Note 20B.
Schedule of financing expenses (Income)	For the year ended December 31 2019 2018 2017 USD thousands Finance expense Fees and interest expense 81 9 26 Loss from exchange rate differences, net 100 106 - Payment to Taoz, see Note 5C - 160 - Warrant issuance costs - 301 - 181 576 26 For the year ended December 31 2019 2018 2017 USD thousands Finance income Income from exchange rate differences, net - - (22 ) Interest income from short term deposits (151 ) (93 ) (106 ) (151 ) (93 ) (128 )

Employee Benefits (Tables)

Employee Benefits (Tables)	12 Months Ended
	Dec. 31, 2019
Employee Benefits [Abstract]
Schedule of post-employee benefits	For the Year ended December 31 2019 2018 USD thousands USD thousands Short-term benefits 365 136 Post-employment benefits 285 405
Schedule of defined contribution plan in respect of its employees	For the Year ended December 31 2019 2018 2017 USD thousands USD thousands USD thousands Amount recognized as expense in respect of defined contribution plan 136 95 52

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of detailed information about financial instruments [abstract]
Schedule of sensitivity test to possible changes in USD/NIS exchange rate	Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 2 5 106 (5 ) (2 ) Other current assets 9 22 440 (22 ) (9 ) Accounts payable (18 ) (45 ) (903 ) 45 18 Other payables (20 ) (49 ) (985 ) 49 20 Post-employment benefit liabilities (2 ) (5 ) (101 ) 5 2 Total income (loss) (29 ) (72 ) 72 29
Schedule of financial instruments measured at fair value	December 31, 2019 Level 1 Level 2 Level 3 Total USD thousands Financial assets Loan - - 2,000 2,000 December 31, 2018 Level 1 Level 2 Level 3 Total USD thousands Financial liabilities Warrants (see Note 9D(2)) - - 554 554
Schedule of fair value measurement	Financial instrument Valuation method for determining fair value Significant unobservable inputs For the year ended December 31, 2019 Warrants Black - Scholes expected term 4.02-4.83 years expected volatility 99 % annual risk free interest 1.95 % dividend yield 0 % For the year ended December 31, 2018 Warrants Black - Scholes expected term 4.9 years expected volatility 97.29 % annual risk free interest 2.51 % dividend yield 0 %

General (Details)

General (Details) - USD ($) $ in Thousands	Mar. 14, 2019	Nov. 30, 2015	Dec. 31, 2019	Dec. 31, 2018
General (Textual)
Accumulated deficit			$ (49,522)	$ (43,672)
Current development plans, description	The Company signed an agreement to acquire 100% of FameWave Ltd, a privately held biopharmaceutical Company with rights to develop CM-24, ("FameWave") from its shareholders in exchange for USD 10 million worth of its newly issued ADSs with a long term lock-up period, priced at USD 1.23 per ADS, plus 50% warrant coverage based on an exercise price of USD 1.98 per ADS with a 4 year term. The acquisition was subject to several conditions, which have been met as of January 7, 2020. In addition, the Company provided a loan to FameWave of USD 2 million that served mainly to pay cCAM BioTherapeutics Ltd., a wholly owned subsidiary of Merck Sharp and Dohme Corp., known as "MSD" in Israel, which discovered CM-24, and to finance budgeted expenses until the closing of the acquisition. See also Note 20B.
Description of warrants to purchase ADS		Each ADS represents 1 ordinary share with no par value following a reverse split in effect from January 4, 2019 (see Note 9A). Each warrant enables the purchase of 1 ADS.
Contract to acquire, percentage	100.00%

Basis of Preparation of the C_3

Basis of Preparation of the Consolidated Financial Statements (Details) - Bank Of Israel [Member] - NIS	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Foreign Exchange Rates [Line Items]
Representative exchange rate of USD (NIS/USD 1)	3.456	3.748	3.467
Changes in exchange rates for the Year ended	(7.80%)	8.10%	(9.80%)

Basis of Preparation of the C_4

Basis of Preparation of the Consolidated Financial Statements (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Recognized right-of-use assets	$ 206
Depreciation expenses	178	7	$ 4
Financing expenses	$ 181	576	$ 26
IFRS 16 [Member]
Discount rate lease liability	8.00%
Recognized right-of-use assets	$ 206	400
Lease liabilities amount	223	$ 400
Depreciation expenses	168
Financing expenses	$ 33

Significant Accounting Polici_3

Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2019
Buildings [Memebr]
Significant Accounting Policies (Textual)
Depreciation of right-of-use asset	2 years
Motor Vehicles [Member] | Bottom of range [Member]
Significant Accounting Policies (Textual)
Depreciation of right-of-use asset	2 years
Motor Vehicles [Member] | Top of range [Member]
Significant Accounting Policies (Textual)
Depreciation of right-of-use asset	3 years

Operating Segments (Details)

Operating Segments (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues		$ 1,000	$ 1,000	$ 100	[1]
Research and development expenses		2,674	5,268	4,640
Operating loss		7,156	7,826	11,966	[1]
Finance income, net		(1,479)	(2,257)	947
Tax Expenses		216
Loss for the year		5,893	5,569	12,913
Pain and Hypertension [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues		1,000	1,000	100
Research and development expenses		395	2,185	2,603
Operating loss		3,068	4,730	6,674
Oncology [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues
Research and development expenses		2,041	2,537	1,328
Operating loss		2,815	3,217	1,951
Total Reportable Segments [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues		1,000	1,000	100
Research and development expenses		2,436	4,722	3,931
Operating loss		5,883	7,947	8,625
Reconciliations [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues	[2]
Research and development expenses	[2]	238	546	709
Operating loss	[2]	$ 1,273	$ 121	$ 3,341
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).
[2]	Includes employees share based expenses and other expenses/income related to rights granted to Taoz.

Operating Segments (Details Tex

Operating Segments (Details Textual)	12 Months Ended
	Dec. 31, 2019Segments
Disclosure of operating segments [abstract]
Number of reportable segments	2

Subsidiary (Details)

Subsidiary (Details) $ in Thousands	Jan. 13, 2017USD ($)
Subsidiary [Abstract]
Cash	$ 2,000
Equity instruments issued (564,625 Ordinary Shares)	1,800	[1]
Assignment of loan to the Company	(101)
Total consideration transferred	$ 3,699
[1]	The fair value of the Ordinary Shares issued was based on the listed share price of the Group on January 11, 2017 of approximately USD 3.19 per share.

Subsidiary (Details 1)

Subsidiary (Details 1) $ in Thousands	Jan. 13, 2017USD ($)
Subsidiary [Abstract]
Current assets	$ 21
Fixed assets, net	3
Intangible assets	6,172	[1]
Short-term credit from bank	(16)
Trade payables	(123)
Other payables	(212)
Long-term related parties	(130)
Total net identifiable assets	$ 5,715
[1]	In-process research and development

Subsidiary (Details 2)

Subsidiary (Details 2) - Tyr Novo Ltd [Member]	12 Months Ended
	Dec. 31, 2019
Disclosure of subsidiaries [line items]
Name of subsidiary	TyrNovo Ltd.
Country of incorporation of subsidiary	Israel
Group's ownership equity	98.47%

Subsidiary (Details Textual)

Subsidiary (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jan. 13, 2017	Aug. 08, 2018	Dec. 31, 2018	Jun. 30, 2018	Oct. 31, 2017	Jan. 11, 2017
Disclosure of detailed information about business combination [line items]
Cash proceeds	$ 2,000
Percentage of ordinary shares acquired				4.10%	27.00%
Ordinary shares issued	564,625			140,845
Cash consideration paid	$ 167	$ 160
Fair value of ordinary shares issued price per share						$ 3.19
Tyr Novo Ltd [Member]
Disclosure of detailed information about business combination [line items]
Cash proceeds	$ 2,000
Percentage of ordinary shares acquired	65.00%
Ordinary shares issued	9,570				658,484
Loans	$ 101
Goldman Hirsh Partners Ltd [Member]
Disclosure of detailed information about business combination [line items]
Cash proceeds			$ 76
Ordinary shares issued	564,625
Cash consideration paid			$ 91

Subsidiary (Details Textual 1)

Subsidiary (Details Textual 1) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Feb. 09, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018	Oct. 31, 2017
Subsidiary [Abstract]
Description of acquiree	A shareholder owning at that time approximately 4% of TyrNovo, entered into a settlement arrangement in response to a motion filed by Taoz on January 19, 2017.
Measurement of issued and outstanding share capital, description	Taoz was entitled to be issued an additional 77 ordinary shares of TyrNovo, representing 0.5% of the issued and outstanding share capital of TyrNovo immediately following this issuance. The shares were issued in February 2017 and were measured at a fair value of USD 29 thousand.
Description of measurement basis for non-controlling interest	Taoz had the right during a defined period to invest an additional USD 1,750,000 (the "Deferred Investment") by way of convertible loans, with conversion terms defined under various circumstances, including the possibility of conversion at a price per share reflecting a 30% discount off the price per share paid in a subsequent financing round, and the possibility of conversion at a price per TyrNovo share reflecting a TyrNovo company valuation of USD 13,500,000.
Percentage of voting equity interests acquired					4.10%	27.00%
Provided to Taoz a put option to sell, description	The Company provided to Taoz a put option to sell to the Company up to 50% of the TyrNovo shares issued to Taoz, exercisable during a period of 90 days from the publication by TyrNovo of the results of Phase I clinical trials, for a price per TyrNovo share equal to USD 1,600, either in ordinary shares of the Company or, at the Company' sole discretion, in cash; upon the expiration of the 90 day exercise period, the put option, if not exercised by Taoz, shall expire and no longer be valid.
Rights granted, share options granted	$ 1,000			$ 1,030
Other expenses				29
Finance expense		181	$ 576	$ 26
Price per share	$ 476.48
Other income		$ 894

Subsidiary (Details Textual 2)

Subsidiary (Details Textual 2) - USD ($) $ in Thousands	Mar. 15, 2018	Jun. 30, 2018	Jun. 15, 2018	Oct. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 13, 2017
Disclosure of detailed information about business combination [line items]
Acquisition of additional stake percentage				27.00%
Percentage of ordinary shares acquired		4.10%		27.00%
Held in ordinary shares				4,024
Percentage of issued and outstanding share capital				6.00%
Ordinary shares issued		140,845						564,625
Carrying amount of net assets on date of the acquisition		$ 1,977		$ 2,821
Decrease in non-controlling interests		93		768
Increase in share premium		237		1,483
Decrease in a capital reserve for transactions with non-controlling interest		144		$ 715
Percentage of issued and outstanding ordinary shares	91.90%		97.40%
Fair value of the shares issued in consideration for waving the rights amount		136
Derivative financial liabilities		1,030
Increase in share premium deriving from the waiving of the rights		$ 136
Finance expense					$ 181	$ 576	$ 26
Minimum [Member]
Disclosure of detailed information about business combination [line items]
Group's ownership equity					97.60%
Maximum [Member]
Disclosure of detailed information about business combination [line items]
Group's ownership equity					98.47%
Tyr Novo Ltd [Member]
Disclosure of detailed information about business combination [line items]
Percentage of ordinary shares acquired								65.00%
Ordinary shares issued				658,484				9,570
Direct ownership of equity					13,750
Group's ownership equity					98.47%

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents	$ 4,385	$ 5,163	$ 3,947	$ 6,758
USD [Member]
Disclosure Of Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents	4,279	4,410
Other currencies [Member]
Disclosure Of Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents	$ 106	$ 753

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Other Current Assets [Abstract]
Receivables, see Note 14	$ 1,493
Government authorities	182	81
Reimbursement of legal fees receivable		743
Prepaid fee to the Food and Drug Administration		930
Prepaid expenses and other receivables	232	76
Total other current assets	$ 1,907	$ 1,830

Other Payables (Details)

Other Payables (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Trade and other payables [abstract]
Contract liabilities, see Note 14	$ 961
Due to related parties - payroll related	587	910
Due to GHP (Note 5A)		167
Accrued expenses	255	852
Government authorities	36	65
Payroll related payables	267	61
Other Payables Total	$ 2,106	$ 2,055

Equity (Details)

Equity (Details) - shares	Dec. 31, 2019	Dec. 31, 2018
Preferred Class D [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	10,000,000	10,000,000
Number of shares, Issued and paid-in
Preferred Class C [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	10,000,000	10,000,000
Number of shares, Issued and paid-in
Preferred Share Class B [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	10,000,000	10,000,000
Number of shares, Issued and paid-in
Preferred Share Class [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	10,000,000	10,000,000
Number of shares, Issued and paid-in
Preferred Class E [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	10,000,000	10,000,000
Number of shares, Issued and paid-in
Ordinary Share [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	250,000,000	250,000,000
Number of shares, Issued and paid-in	19,564,000	16,099,000

Equity (Details 1)

Equity (Details 1) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Changes in equity [abstract]
Issued as at January 1	16,009,000	11,222,000	7,662,000
Issuance of ADSs (See D below)	3,429,000	3,260,000	2,432,000
Issuance of shares (See Note 5)		799,000	565,000
Vesting of RSUs	97,000	121,000	563,000
Exercise of warrants	29,000	607,000
Issued as at December 31	19,564,000	16,009,000	11,222,000

Equity (Details 2)

Equity (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Noncontrolling Interests [Line Items]
Current assets	$ 8,302	$ 8,514
Current liabilities	3,546	3,314
Loss allocated to non-controlling interests	$ 43	$ 369	$ 736
Non-controlling interests [member] | Tyr Novo Ltd [Member]
Noncontrolling Interests [Line Items]
Non-controlling interests percentage	1.53%	2.40%
Non-current assets	$ 24	$ 9
Current assets	192	415
Current liabilities	(646)	(4,120)
Net assets	(430)	(3,696)
Net assets attributable to non-controlling interests	(7)	(89)
Loss for the year	2,847	3,688
Loss allocated to non-controlling interests	$ 43	$ 369

Equity (Details Textual)

Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Oct. 30, 2017	Sep. 30, 2019	Jan. 31, 2019	Dec. 19, 2018	Jun. 30, 2018	Dec. 31, 2017	Oct. 31, 2017	Jul. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Feb. 09, 2017
Equity (Textual)
Placement agent fees									$ 900	$ 1,525	$ 1,306
Public offering issued by securities								29
Public offering issued value								$ 43
Public offering price per unit												$ 476.48
Description of warrants rights										During 2018 343 thousand warrants, issued in July 2017, were exercised into 343 thousand shares for a consideration of USD 515 thousand. In addition, 484 thousand warrants, issued in July 2017, were exercised into 264 thousand shares on a cashless exercise, and an amount of USD 1,618 thousand was recorded to share premium against derivative liabilities.
Company issued securities, description				The Company's authorized and paid-in share capital in a 20:1 ratio, in a way that every 20 shares with no par value were consolidated into one share with no par value. The said reverse share split took place on January 4, 2019. Following the reverse share split, the Company's authorized share capital is 250,000,000 ordinary shares, with no par value, and 50,000,000 non-voting senior preferred shares, with no par value, divided into 5 classes of 10,000,000 preferred shares in each class.
Ordinary shares of vested restricted stock units										97	97
Ordinary shares restricted stock units										$ 121
Share premium								42	$ 46,986	44,597
Warrants fair value		$ 661
Ordinary Share [Member]
Equity (Textual)
Ordinary shares of vested restricted stock units						496,533	496,533
Public Offering [Member]
Equity (Textual)
Company funds raised			$ 6,000		$ 8,100			3,500
Placement agent fees			$ 5,100		$ 7,400			$ 3,100
Public offering issued by securities			3,428,572
Public offering price per unit			$ 2
Warrants to purchase shares of common stock			2,571,430
Proceeds from exercise of warrants			$ 298
Non-listed warrants			2,571,430
Company issued securities, description			The ADSs issued were recorded in equity in an amount of USD 2,200 thousand, net of issuance expenses. The warrants were considered a derivative instrument (due to a cashless exercise feature), and were recorded as a liability in the amount of USD 3,406 thousand. Issuance expenses related to the warrants, in the amount of USD 515 thousand were recorded to finance expense. During September 2019, the warrants were listed for trading, as a result the cashless feature expired. Therefore the Company reclassified the warrants to equity according to the warrants fair value on the listing date. The changes in the warrants fair value was recorded as financial income. The warrants fair value on the listing date was USD 1,273 thousand. See also Note 20B.
Issue of equity			$ 2,200
Finance expenses			169
Share premium			$ 129
Ads [Member]
Equity (Textual)
Concurrent private placement issued					3,260,000			2,431,746
Warrant exercise price					$ 2.80			$ 1.50
Warrants to purchase shares of common stock					1,630,000			1,215,873
Adjusted value of warrants					$ 3,467
Shares to service providers for services granted	67,367
Shares to service providers for services granted, value	$ 150
General and administrative expenses										$ 54	$ 96
Non-listed warrants					1,630,000			1,215,873
Issue of equity					$ 4,276			$ 2,174
Finance expenses					$ 301
Warrants fair value								$ 567

Share-based Payment Arrangeme_3

Share-based Payment Arrangements (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Weighted average exercise prices (in USD)
Outstanding on January 1	$ 2.6	$ 3.08	$ 4.29
Expired during the year		7	20.72
Granted during the year	1.32	1.59	1.85
Outstanding on December 31	1.71	2.6	3.08
Exercisable on December 31	$ 3.21	$ 2.95	$ 2.83
Number of options
Outstanding on January 1	1,131,781	1,002,022	519,746
Expired during the year		30,000	2,239
Granted during the year	3,622,895	159,759	484,515
Outstanding on December 31	4,754,676	1,131,781	1,002,022
Exercisable on December 31	1,093,029	873,344	708,879

Share-based Payment Arrangeme_4

Share-based Payment Arrangements (Details 1) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of RSUs
Outstanding at January 1	109,419	170,727
Granted during the year		59,720
Vested during the year	97,910	121,028
Outstanding at December 31	11,509	109,419

Share-based Payment Arrangeme_5

Share-based Payment Arrangements (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of range of exercise prices of outstanding share options [line items]
Share Price - USD		$ 1.18
Option price - USD		$ 0.80
Expected volatility (%)		105.77%
Expected duration (years)		4 years 11 months 12 days
Dividend yield (%)
Risk free rate interest rate (%)		1.41%
Top of range [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Share Price - USD	$ 1.22		$ 2.17
Option price - USD	$ 1.1		$ 3.82
Expected volatility (%)	113.78%		80.91%
Expected duration (years)	7 years		6 years 11 months 19 days
Risk free rate interest rate (%)	1.95%		1.39%
Bottom of range [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Share Price - USD	$ 0.746		$ 1.82
Option price - USD	$ 0.49		$ 3.28
Expected volatility (%)	99.22%		80.65%
Expected duration (years)	4 years 7 months 10 days		6 years 9 months 7 days
Risk free rate interest rate (%)	1.63%		1.36%
Option pricing model [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Share Price - USD		$ 368.39
Option price - USD		$ 369.39
Expected volatility (%)		79.16%
Expected duration (years)		7 years
Dividend yield (%)
Risk free rate interest rate (%)		2.40%

Share-based Payment Arrangeme_6

Share-based Payment Arrangements (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangements [Abstract]
Research and development expenses	$ 238	$ 546	$ 709
General and administrative expenses	1,035	227	1,570
Other expenses			29
Total share-based expense recognized	$ 1,273	$ 773	$ 2,308

Share-based Payment Arrangeme_7

Share-based Payment Arrangements (Details Textual) $ / shares in Units, $ in Thousands

Nov. 20, 2018USD ($)$ / sharesshares

Jan. 03, 2018USD ($)$ / sharesshares

Aug. 15, 2017USD ($)Consultants$ / sharesshares

Aug. 01, 2017USD ($)$ / sharesshares

Dec. 23, 2019USD ($)$ / sharesshares

Apr. 30, 2019

Mar. 31, 2019

Jun. 30, 2017shares

May 22, 2016

Nov. 25, 2015

Dec. 31, 2019USD ($)$ / shares

Dec. 31, 2018USD ($)$ / shares

Dec. 31, 2017$ / shares

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Additional ordinary shares | shares

1,900,000

Weighted average remaining contractual life

5 years 6 months 21 days

5 years 3 months 15 days

7 years 2 months 12 days

Key management personnel, description

The Company recorded in 2019 an expense of USD 1,273 thousand (2018 - USD 719 thousand), of which USD 988 thousand (2018 - USD 660 thousand) are to key management personnel.

Bottom of range [member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Options exercise price | $ / shares

$ 0.81

$ 1.59

$ 1.84

Top of range [member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Options exercise price | $ / shares

$ 6

$ 4.39

$ 7.01

Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of shares approved | shares

400

Vesting period

3 years

Exercise period

7 years

Options exercise price | $ / shares

$ 0.814

Fully vested grant | shares

8

Fair value of options and grants measured | $

$ 15

Stock option granted | $

$ 207

Rsu [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Fully vested grant | shares

28

Fair value of options and grants measured | $

$ 76

Directors and Officers [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Exercise period

7 years

Directors and Officers [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant | shares

20

Fair value of options and grants measured | $

$ 592

Stock option granted | $

$ 17

Additional number of shares issued | shares

440

Number of consultants | Consultants

2

Directors and Officers [Member] | Rsu [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant | shares

22

Fair value of options and grants measured | $

$ 1,326

Restricted stock units | $

$ 29

Additional number of shares issued | shares

608

Number of consultants | Consultants

2

Board of Directors [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Options exercise price | $ / shares

$ 1.85

Board of Directors [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Additional number of shares issued | shares

16

Board of Directors [Member] | Rsu [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Additional number of shares issued | shares

42

Tmura [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fair value expense | $

$ 56

Options exercise price | $ / shares

$ 6

Stock option granted | $

$ 61

Two Executives [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of shares approved | shares

159,759

Two Executives [Member] | Rsu [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of shares approved | shares

59,720

Offeree [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Exercise period

5 years

Options exercise price | $ / shares

$ 1.59

Fair value of options and grants measured | $

$ 127

Offeree [Member] | Rsu [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant | shares

34,825

Fair value of options and grants measured | $

$ 71

Service Provider [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Exercise period

7 years

Options exercise price | $ / shares

$ 1.84

Number of consultants | Consultants

2

Service Provider [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant | shares

29

Fair value of options and grants measured | $

$ 31

Service Provider [Member] | Rsu [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant | shares

9

Fair value of options and grants measured | $

$ 32

Chairman of Board of Directors [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

7 years

Options exercise price | $ / shares

$ 4.39

Number of consultants | Consultants

1

Tyrnovo [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Exercise period

7 years

Key management personnel | $

$ 431

Options exercise price | $ / shares

$ 0.29

Fair value of options and grants measured | $

$ 431

Number of grant option shares | shares

1,170

Share-based compensation expense | $

$ 402

Directors And Officers [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Stock option related, description

The board of directors of the Company approved the grant of 3,162 thousand options to directors, employees and consultants. The options have an exercise price of USD 1.28 – 1.64 per one ordinary share, and will vest during 3 years from the date of grant. The options are exercisable for 5-7 years from grant date. The fair value of these options as of the grant date was measured at USD 2,677 thousand.

The board of directors of the Company approved the grant of 3,162 thousand options to directors, employees and consultants. The options have an exercise price of USD 1.28 – 1.64 per one ordinary share, and will vest during 3 years from the date of grant. The options are exercisable for 5-7 years from grant date. The fair value of these options as of the grant date was measured at USD 2,677 thousand.

Transactions and Balances wit_3

Transactions and Balances with Related Parties (Details) - Payments To Key Management [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Directors [Member]
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Short - term employee benefits	$ 339	$ 268	$ 217
Share based payments	269	86	236
Total	608	354	453
Chief Executive Officer [Member]
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Short - term employee benefits	1,776	2,165	2,305
Post-employment benefits	22	16	137
Share based payments	719	574	1,669
Total	$ 2,517	$ 2,755	$ 4,111

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details Textual) ₪ in Thousands, $ in Thousands

Nov. 08, 2016

Jul. 31, 2018USD ($)

Mar. 20, 2017

Feb. 28, 2017USD ($)

Feb. 28, 2017ILS (₪)

Feb. 10, 2017

Feb. 07, 2017

Dec. 31, 2019USD ($)

Dec. 31, 2019ILS (₪)

Dec. 31, 2015USD ($)

Dec. 31, 2015ILS (₪)

Aug. 13, 2019USD ($)

Aug. 13, 2019ILS (₪)

Commitments and Contingent Liabilities (Textual)

Motion total amount

$ 4,300

Description, of lawsuit filing

The Company delivered its response to the court in accordance with applicable law. A preliminary hearing held by the court on September 12, 2016 and subsequently the court set a schedule for the submission by the petitioners of a motion for discovery, and any responses to such motion.

The Company delivered its response to the court in accordance with applicable law. A preliminary hearing held by the court on September 12, 2016 and subsequently the court set a schedule for the submission by the petitioners of a motion for discovery, and any responses to such motion.

Loss contingency actions taken by court arbitrator or mediator, description

The Motion to be excluded from the purported class and claiming to have independent causes of action and claims of approximately NIS 1 million (USD 262 Thousand) (the “Petition to Exclude”). The Company responded to the court as required, and, amongst other arguments, the Company noted that such shareholder cannot petition to be excluded from the purported class. The court ordered the shareholder to respond and he has done so. In May 2018 the shareholder submitted an independent lawsuit against the Company in the Haifa Magistrates Court seeking damages of approximately NIS 1.1 million (USD 306 Thousand) (the “Separate Lawsuit”).

Gains on litigation settlements

$ 8,000

Initial public offering date

Nov. 20, 2015

Nov. 20, 2015

Nov. 20, 2015

Aggregate consideration received

$ 2,000

Fine paid by company

$ 1,500

TryNovo's Technologies [Member] | Israel Innovation Authority [Member]

Commitments and Contingent Liabilities (Textual)

Maximum royalty payable excluding interest amount

$ 1,600

Yissum [Member]

Commitments and Contingent Liabilities (Textual)

Description of license agreement

In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license: (i) Royalties at a rate of three percent (3%) of net sales. (ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration. In addition, Yissum is entitled to receive an exit fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement.

In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license: (i) Royalties at a rate of three percent (3%) of net sales. (ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration. In addition, Yissum is entitled to receive an exit fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement.

Bottom of range [member]

Commitments and Contingent Liabilities (Textual)

Annual interest rate of revenues

3.00%

3.00%

Top of range [member]

Commitments and Contingent Liabilities (Textual)

Annual interest rate of revenues

6.00%

6.00%

NIS [Member]

Commitments and Contingent Liabilities (Textual)

Motion total amount | ₪

₪ 16,400

Gains on litigation settlements | ₪

₪ 29,000

Fine paid by company | ₪

₪ 430

NIS [Member] | TryNovo's Technologies [Member] | Israel Innovation Authority [Member]

Commitments and Contingent Liabilities (Textual)

Maximum royalty payable excluding interest amount | ₪

₪ 5,500

Research and Development Expe_3

Research and Development Expenses (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Research and Development Expenses [Abstract]
Salaries, wages and related expenses		$ 1,012	$ 933	$ 969
Share-based payments		238	546	709
Service Providers	[1]	1,424	3,789	2,962
Research and development expense		$ 2,674	$ 5,268	$ 4,640
[1]	The Company has determined that it acts as an agent for certain transactions, see Note 3I. Accordingly, the Company recorded USD 532 thousand as an offset of R&D costs. Receivables and payables regarding such transactions are recorded on a gross basis (see Notes 7 and 8, respectively).

Sales, General and Administra_3

Sales, General and Administrative Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
General and Administrative Expenses [Abstract]
Employees and officers compensation	$ 1,445	$ 1,733	$ 1,984
Share-based payments (see also Note 10)	657	87	1,224
Legal fees in connection with ISA investigation and class action lawsuits (see also Note 12B)	356	690	893
Other professional consulting	900	1,525	1,306
Board member remuneration and insurance	622	470	505
Board member share-based payments	269	86	47
FDA Fee	946
ISA settlement (see also Note 12B)	387
Rent and office maintenance	80	243	196
Travel	144	143	131
Car expenses	38	85	64
Depreciation	178	7	4
Other	56	126	43
General and Administrative Expenses	$ 6,078	$ 5,195	$ 6,397

Sales, General and Administra_4

Sales, General and Administrative Expenses (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
General and Administrative Expenses (Textual)
Legal expenses	$ 596	$ 743

Other Expenses (Income) (Detail

Other Expenses (Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other Expenses (Income) (Textual)
Other expenses (income)		$ (894)	$ 1,029

Finance Expense (Income) (Detai

Finance Expense (Income) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Finance Expense (Income) [Abstract]
Income (expenses) in respect of derivatives, net	[1]	$ (1,509)	$ (2,740)	$ 1,049
[1]	The derivatives are related mainly to the fair value adjustments of warrants. The 2019, 2018 and 2017 warrants included a cashless exercise feature, which expired on September 16, 2019, September 12, 2019 and August 8, 2018, respectively, when the Company filed a registration statement with the SEC, registering the shares that will derive from future exercise of these warrants. See also Note 20B.

Finance Expense (Income) (Det_2

Finance Expense (Income) (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Finance expense
Fees and interest expense	$ 81	$ 9	$ 26
Loss from exchange rate differences, net	100	106
Payment to Taoz, see Note 5C		160
Warrant issuance costs		301
Finance expense	181	576	26
Finance income
Income from exchange rate differences, net			(22)
Interest income from short term deposits	(151)	(93)	(106)
Finance income	$ (151)	$ (93)	$ (128)

Taxes on Income (Details)

Taxes on Income (Details) - Corporate Tax Rate [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Taxes on Income (Textual)
Corporate tax rate	23.00%	23.00%	24.00%
Unrecognized research and development expenses	$ 21,000	$ 33,100	$ 28,200
Taxes on income, description	In 2019, the main reconciling item from the statutory tax rate of the Company (23%, representing theoretical tax benefit of approximately USD 1.3 million) to the effective tax rate (0%) is the fact that deferred taxes were not created in respect of carry forward tax losses.

Employee Benefits (Details)

Employee Benefits (Details) - Separate Management Entitie [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Short-term benefits	$ 365	$ 136
Post-employment benefits	$ 285	$ 405

Employee Benefits (Details 1)

Employee Benefits (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Employee Benefits [Abstract]
Amount recognized as expense in respect of defined contribution plan	$ 136	$ 95	$ 52

Employee Benefits (Details Text

Employee Benefits (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Employee Benefits (Textual)
Employee benefit bonus	$ 462	$ 777
Employee benefits liability due grants	$ 285	$ 405

Financial Instruments (Details)

Financial Instruments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Down 2%
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	$ (29)
Down 5%
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(72)
Up 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	72
Up 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	29
Cash and cash equivalents and deposits [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) value	106
Cash and cash equivalents and deposits [Member] | Down 2%
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	2
Cash and cash equivalents and deposits [Member] | Down 5%
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	5
Cash and cash equivalents and deposits [Member] | Up 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(5)
Cash and cash equivalents and deposits [Member] | Up 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(2)
Other current assets [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) value	440
Other current assets [Member] | Down 2%
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	9
Other current assets [Member] | Down 5%
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	22
Other current assets [Member] | Up 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(22)
Other current assets [Member] | Up 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(9)
Accounts payable [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) value	(903)
Accounts payable [Member] | Down 2%
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(18)
Accounts payable [Member] | Down 5%
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(45)
Accounts payable [Member] | Up 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	45
Accounts payable [Member] | Up 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	18
Other payables [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) value	(985)
Other payables [Member] | Down 2%
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(20)
Other payables [Member] | Down 5%
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(49)
Other payables [Member] | Up 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	49
Other payables [Member] | Up 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	20
Post-employment benefit liabilities [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) value	(101)
Post-employment benefit liabilities [Member] | Down 2%
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(2)
Post-employment benefit liabilities [Member] | Down 5%
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(5)
Post-employment benefit liabilities [Member] | Up 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	5
Post-employment benefit liabilities [Member] | Up 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	$ 2

Financial Instruments (Details

Financial Instruments (Details 1) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Financial assets
Loan	$ 2,000
Financial liabilities
Warrants		554
Level 1 [Member]
Financial assets
Loan
Financial liabilities
Warrants
Level 2 [Member]
Financial assets
Loan
Financial liabilities
Warrants
Level 3 [Member]
Financial assets
Loan	$ 2,000
Financial liabilities
Warrants		$ 554

Financial Instruments (Detail_2

Financial Instruments (Details 2) - Warrants [Member] - Black Scholes [Member]	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disclosure of continuing involvement in derecognised financial assets [line items]
expected term		4 years 10 months 25 days
expected volatility	99.00%	97.29%
annual risk free interest	1.95%	2.51%
dividend yield	0.00%	0.00%
Top of range [member]
Disclosure of continuing involvement in derecognised financial assets [line items]
expected term	4 years 7 days
Bottom of range [member]
Disclosure of continuing involvement in derecognised financial assets [line items]
expected term	4 years 9 months 29 days

Financial Instruments (Detail_3

Financial Instruments (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Financial Instruments (Textual)
Cash and cash equivalents and short term deposits	$ 4,395	$ 6,684
Loan to farm wave	$ 2,000
Intangible asset discount rate	20.00%
Bottom of range [member]
Financial Instruments (Textual)
Short term deposits fixed interest rate	0.02%
Top of range [member]
Financial Instruments (Textual)
Short term deposits fixed interest rate	2.97%

Subsequent Events (Details)

Subsequent Events (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Ads [Member] | March 2020 [Member]
Subsequents Event (Textual)
Public offering description	The Company issued 9,620,000 ADSs and 10,380,000 pre-funded warrants, 20,000,000 warrants to purchase 20,000,000 ADSs. Each pre-funded warrant is exercisable until March, 2035 at an exercise price of USD 0.0001 and each warrant is exercisable until March, 2025 at an exercise price of USD 0.325 per ADS. In addition, the placement agent in this offering was granted 1,400,000 warrants to purchase 1,400,000 ADSs exercisable until March, 2025 at an exercise price of USD 0.375 per ADS. The Company will also issue 250,000 ADS in a private placement to the previous placement agent in this transaction.
Nasdaq [Member] | March 2020 [Member]
Subsequents Event (Textual)
Gross amount of placement agent fees	$ 6,000
Net of placement agent fees and other offering related expenses	$ 5,200
Famewave Ltd [Member] | Ads [Member] | March 14, 2019 [Member]
Subsequents Event (Textual)
Agreement description	The agreement, OrbiMed, Pontifax and Arkin Holdings, leading life-science focused investment funds, are exchanging their shares in FameWave for Kitov ADSs and warrants, and investing USD 3.5 million in Kitov in exchange for additional newly issued ADSs of Kitov. As of January 7, 2020, OrbiMed, Pontifax and Arkin Holdings each hold approximately 11% of Kitov’s shares on a non-diluted basis.
Agreement to acquire description	The Company signed an agreement to acquire 100% of FameWave Ltd, a privately held biopharmaceutical Company developing CM-24, (“FameWave”) from its shareholders in exchange for USD 10 million worth of its newly issued ADSs with a long-term lock-up period, priced at USD 1.23 per ADS, plus 50% warrant coverage based on an exercise price of USD 1.98 per ADS with a 4-year term. In addition, the Company provided a loan to FameWave of up to approximately USD 2 million to be paid to cCAM BioTherapeutics Ltd., a wholly owned subsidiary of Merck Sharp and Dohme Corp., known as “MSD” in Israel, which discovered CM-24, or to repay certain loans provided by FameWave’s shareholders. The acquisition closed in January 7, 2020.